View Filing Data

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMATION - USD ($)	Oct. 31, 2012	Feb. 13, 2013	Apr. 30, 2012
Entity Registrant Name	ADVAXIS, INC.
Entity Central Index Key	0001100397
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	adxs
Entity Common Stock, Shares Outstanding		502,052,901
Document Type	10-K
Amendment Flag	false
Document Period End Date	Oct. 31, 2012
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2012
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 35,567,624

BALANCE SHEET - USD ($)	Oct. 31, 2012	Oct. 31, 2011
ASSETS
Cash	$ 232	$ 1,096,538
Other Current Receivable	0	477,788
Prepaid expenses	25,798	37,474
Other Current Assets	8,182	2,221
Deferred Expenses - current	860,293	0
Total Current Assets	894,505	1,614,021
Deferred expenses - long-term	342,007	1,380,103
Property and Equipment (net of accumulated depreciation)	78,068	0
Intangible Assets (net of accumulated amortization)	2,413,755	2,256,852
Deferred Financing Cost (net of accumulated amortization)	49,024	65,848
Other Assets	38,438	38,438
TOTAL ASSETS	3,815,797	5,355,262
LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Accounts payable	5,155,797	2,420,260
Accrued Expenses	1,367,412	2,976,334
Short-term Convertible Notes and fair value of embedded derivative	2,089,099	5,091,298
Notes payable - Officer (including interest payable)	477,274	408,069
Notes payable - other	250,000	0
Total Current Liabilities	9,339,582	10,895,961
Deferred Rent	4,803	62,441
Long-term Convertible Notes	0	570,802
Common Stock Warrant Liability	434,136	6,391,071
Total Liabilities	9,778,521	17,920,275
Commitments and Contingencies
Shareholders' Deficiency:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at October 31, 2012 and 2011. Liquidation preference of $9,722,570
Common Stock - $0.001 par value; authorized 1,000,000,000 shares, issued and outstanding 394,804,165 in 2012 and 250,173,570 in 2011	394,804	250,173
Promissory Note and Interest Receivable	(10,484,022)	(10,283,510)
Additional Paid-In Capital	51,727,921	33,000,064
Deficit accumulated during the development stage	(47,601,427)	(35,531,740)
Total Shareholders' Deficiency	(5,962,724)	(12,565,013)
TOTAL LIABILITIES & SHAREHOLDERS' DEFICIENCY	$ 3,815,797	$ 5,355,262

BALANCE SHEET [Parenthetical] - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Apr. 04, 2011	Oct. 31, 2010
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued		740
Preferred stock, shares outstanding	740	740
Liquidation preference	$ 9,722,570	$ 9,722,570
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	394,804,165	250,173,570
Common stock, shares outstanding	394,804,165	250,173,570
Series A Preferred Stock [Member]
Preferred stock, shares issued	0			0
Preferred stock, shares outstanding	0			0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)			$ 0.001
Preferred stock, shares issued	740	740
Preferred stock, shares outstanding	740	740

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended		128 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Revenue	$ 0	$ 0	$ 1,863,343
Research & Development Expenses	6,646,094	8,078,901	29,802,834
General & Administrative Expenses	5,688,677	4,939,935	26,868,510
Total Operating expenses	12,334,771	13,018,836	56,671,344
Loss from Operations	(12,334,771)	(13,018,836)	(54,808,001)
Other Income (expense):
Interest expense	(4,536,528)	(4,698,983)	(14,985,865)
Other Income (Expense)	12,002	(78,911)	259,709
(Loss) on note retirement	(2,187,787)	(461,595)	(992,942)
Gain on change in fair value of common stock warrant liability and embedded derivative liability	6,630,610	9,763,113	21,042,296
Net Loss before income tax benefit	(12,416,474)	(8,495,212)	(49,484,803)
Income Tax Benefit	346,787	379,472	1,927,260
Net Loss	(12,069,687)	(8,115,740)	(47,557,543)
Dividends attributable to preferred shares	740,000	1,538,686	2,322,570
Net Loss applicable to Common Stock	$ (12,809,687)	$ (9,654,426)	$ (49,880,113)
Net Loss per common share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.04)
Weighted average number of common shares outstanding, basic and diluted (in shares)	320,602,442	222,918,519

STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Promissory Note and Interest Receivable [Member]	Total
Balance at Dec. 31, 2002		$ 15,598	$ 229,895	$ (166,936)		$ 78,557
Balance (in shares) at Dec. 31, 2002		15,597,723
Options granted to consultants			8,484			8,484
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004	$ (15,969)		15,969
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)	(232)
Conversion of Note payable to Stock	$ 15,969					15,969
Conversion of Note payable to Stock (in shares)	232
Options granted to consultants and professionals			8,484			8,484
Net Loss as reported				(909,745)		(909,745)
Balance at Dec. 31, 2003		$ 15,598	254,348	(1,076,681)		(806,735)
Balance (in shares) at Dec. 31, 2003		15,597,723
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004	$ 43,884		(43,884)
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)	638
Options granted to consultants and professionals			5,315			5,315
Net Loss as reported				(538,076)
Balance at Oct. 31, 2004		$ 15,598	303,547	(1,658,641)		(1,339,496)
Balance (in shares) at Oct. 31, 2004		15,597,723
Common Stock issued to Placement Agent on re-capitalization		$ 753	(753)
Common Stock issued to Placement Agent on re-capitalization (in shares)		752,600
Effect Of Re-Capitalization		$ 753	(753)
Effect Of Re-Capitalization (in shares)		752,600
Options granted to consultants			64,924			64,924
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004			(88,824)			(88,824)
Conversion of Note payable to Stock		$ 2,136	611,022			$ 613,518
Conversion of Note payable to Stock (in shares)		2,136,441				2,136,441
Issuance of Common Stock for cash, net of shares to Placement Agent		$ 17,451	4,335,549			$ 4,353,000
Issuance of Common Stock for cash, net of shares to Placement Agent (in shares)		17,450,693
Issuance of Common Stock to employees and directors		$ 587	166,190			166,777
Issuance of Common Stock to employees and directors (in shares)		586,970
Issuance of common stock in connection with the registration statement		$ 408	117,090			117,498
Issuance of common stock in connection with the registration statement (in shares)		409,401
Issuance costs			(329,673)			(329,673)
Options granted to consultants and professionals			64,924			64,924
Net Loss as reported				(1,805,789)
Balance at Oct. 31, 2005		$ 37,686	5,178,319	(3,464,430)		1,751,575
Balance (in shares) at Oct. 31, 2005		37,686,428
Options granted to employees and directors			71,667			71,667
Options granted to consultants			172,831			172,831
Conversion of Note payable to Stock		$ 1,767	298,233			300,000
Conversion of Note payable to Stock (in shares)		1,766,902
Issuance of Common Stock to employees and directors		$ 229	54,629			54,858
Issuance of Common Stock to employees and directors (in shares)		229,422
Options granted to consultants and professionals			172,831			172,831
Issuance of common stock to consultants		$ 557	139,114			139,674
Issuance of common stock to consultants (in shares)		556,240
Net Loss as reported				(6,197,744)		(6,197,744)
Balance at Oct. 31, 2006		$ 40,239	5,914,793	(9,662,173)		(3,707,141)
Balance (in shares) at Oct. 31, 2006		40,238,992
Stock issued		$ 59,228	9,321,674			$ 9,380,902
Stock Issued (in shares)		59,228,334				59,228,334
Options granted to employees and directors			222,501			$ 222,501
Conversion of Note payable to Stock		$ 6,974	993,026			$ 1,000,010
Conversion of Note payable to Stock (in shares)		6,974,202				6,974,202
Issuance of Common Stock to employees and directors		$ 416	73,384			$ 73,800
Issuance of Common Stock to employees and directors (in shares)		416,448
Options granted to consultants and professionals			268,577			268,577
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		416,448
Issuance of common stock to consultants		$ 1,100	220,678			221,778
Issuance of common stock to consultants (in shares)		1,100,001
Offering Costs			(2,243,535)			(2,243,535)
Warrants Issued			1,505,550			1,505,550
Net Loss as reported				(2,454,453)		(2,454,453)
Balance at Oct. 31, 2007		$ 107,957	16,276,648	(12,116,626)		4,267,979
Balance (in shares) at Oct. 31, 2007		107,957,977
Stock Issued (in shares)		211,853
Options granted to consultants			257,854			257,854
Issuance of Common Stock to employees and directors		$ 996	85,005			86,001
Issuance of Common Stock to employees and directors (in shares)		995,844
Options granted to consultants and professionals			(42,306)			(42,306)
Issuance of common stock to consultants		$ 154	14,462			14,616
Issuance of common stock to consultants (in shares)		153,846
Offering Costs			(78,013)			(78,013)
Warrants Issued			39,198			39,198
Common Stock Penalty Shares		$ 212	31,566	0		31,778
Common Stock Penalty Shares (in shares)		211,853
Net Loss as reported				(5,416,418)		(5,416,418)
Balance at Oct. 31, 2008		$ 109,319	16,584,414	(17,533,044)		(839,311)
Balance (in shares) at Oct. 31, 2008		109,319,520
Common Stock Issued Upon Exercise of Warrants		$ 3,300	(3,300)			0
Common Stock Issued Upon Exercise of Warrants (in shares)		3,299,999
Options granted to employees and directors		$ 0	467,304			467,304
Issuance of Common Stock to employees and directors		$ 423	17,757			18,180
Issuance of Common Stock to employees and directors (in shares)		422,780
Options granted to consultants and professionals			12,596			12,596
Issuance of common stock to consultants		$ 2,596	49,383			51,979
Issuance of common stock to consultants (in shares)		2,595,944
Warrant's classified as a liability			(12,785,695)			(12,785,695)
Issuance of common stock warrants			(3,587,625)			(3,587,625)
Net Loss as reported				929,244		929,244
Balance at Oct. 31, 2009		$ 115,638	754,834	(16,603,800)		(15,733,328)
Balance (in shares) at Oct. 31, 2009		115,638,243
Stock issued	$ 0		6,828,293			6,828,293
Stock Issued (in shares)	789
Common Stock Issued Upon Exercise of Warrants		$ 62,265	18,647,522		$ (10,659,710)	(10,659,710)
Common Stock Issued Upon Exercise of Warrants (in shares)		62,265,059
Options granted to employees and directors			455,166			455,166
Common stock issued upon conversion of Bridge Notes		$ 15,414	3,306,677			3,322,091
Common stock issued upon conversion of Bridge Notes (in shares)		15,413,960
Issuance of common stock warrants			(7,693,230)			(7,865,520)
Issuance of Common Stock to employees and directors		$ 750	114,750			115,500
Issuance of Common Stock to employees and directors (in shares)		750,000
Common stock issued to former employees		$ 145	(145)			0
Common stock issued to former employees (in shares)		144,666
Common stock issued to University of Pennsylvania		$ 389	69,611			70,000
Common stock issued to University of Pennsylvania (in shares)		388,889
Issuance of shares under Numoda Stock Purchase Agreement		$ 3,500	591,500			595,000
Issuance of shares under Numoda Stock Purchase Agreement (in shares)		3,500,000
Net Loss as reported				(10,812,200)
Balance at Oct. 31, 2010	$ 0	$ 198,101	23,074,978	(27,416,000)	(10,659,710)	(10,659,710)
Balance (in shares) at Oct. 31, 2010	789	198,100,817
Stock issued	$ 0		1,676,554			1,676,554
Stock Issued (in shares)	177
Common Stock Issued Upon Exercise of Warrants		$ 22,986	5,782,511		(2,389,500)	(2,389,500)
Common Stock Issued Upon Exercise of Warrants (in shares)		22,986,244
Common Stock Issued Upon Exchange of Warrants		$ 5,841	1,528,124			1,533,965
Common Stock Issued Upon Exchange of Warrants (in shares)		5,840,748
Options granted to employees and directors			717,029			717,029
Options granted to consultants			28,197			28,197
Common stock issued upon conversion of Bridge Notes		$ 9,513	1,809,204			1,818,717
Common stock issued upon conversion of Bridge Notes (in shares)		9,513,210
Common stock issued upon conversion of May 2011 Notes		$ 12,647	2,250,536			2,263,183
Common stock issued upon conversion of May 2011 Notes (in shares)		12,647,076
Interest on Optimus Notes					(285,300)	(285,300)
Common stock issued to former employees		$ 752	80,779			81,531
Common stock issued to former employees (in shares)		752,142
Issuance of common stock warrants			(1,228,838)			(1,228,838)
Preferred Stock redeemed	$ 0		(3,141,003)			3,051,000
Preferred Stock redeemed (in shares)	(226)
Reclassification of warrant liability to equity			36,982			36,982
Reclassification of Embedded Derivative Liability to Beneficial Conversion Feature			132,488			132,488
Interest on Optimus Notes Receivable			202,856			202,856
Common Stock issued to consultants		$ 333	49,667			50,000
Common Stock issued to consultants (in shares)		333,333
Net Loss as reported				(8,115,740)		(8,115,740)
Balance at Oct. 31, 2011	$ 0	$ 250,173	33,000,064	0	(10,283,510)	(12,565,013)
Balance (in shares) at Oct. 31, 2011	740	250,173,570
Stock issued						0
Fair value of equity warrants issued in connection with Rodman May 2012 Financing			279,807			279,807
Common Stock Issued Upon Exercise of Warrants		$ 2,745	409,019			411,765
Common Stock Issued Upon Exercise of Warrants (in shares)		2,745,097
Common Stock Issued Upon Exchange of Warrants		$ 1,597	221,999			223,596
Common Stock Issued Upon Exchange of Warrants (in shares)		1,597,112
Common stock issued upon conversion of JMJ Notes		$ 8,326	657,715			666,041
Common stock issued upon conversion of JMJ Notes (in shares)		8,325,927
Options granted to employees and directors						0
Options granted to consultants						0
Common stock issued upon conversion of Bridge Notes						0
Issuance of shares to directors		$ 1,000	31,558			31,558
Issuance of shares to directors (in shares)		999,632
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004						0
Issuance of shares upon conversion of convertible promissory notes		$ 30,429	5,258,120			5,288,549
Issuance of shares upon conversion of convertible promissory notes (in shares)		30,429,180
Issuance of shares to employees under ESPP Plan		$ 207	18,094			18,301
Issuance of shares to employees under ESPP Plan (in shares)		207,077
Issuance of shares to investors as part of the May 2012 Debt for Equity Exchange		$ 52,776	5,996,621			6,049,397
Issuance of shares to investors as part of the May 2012 Debt for Equity Exchange (in shares)		52,776,184
Interest on Optimus Notes			200,512		(200,512,000)	0
Conversion of Note payable to Stock						$ 4,500,000
Conversion of Note payable to Stock (in shares)						52,200,000
Options granted to consultants and professionals	$ 0		1,146,843			$ 1,146,843
Issuance of common stock to consultants		$ 415	39,442			39,857
Issuance of common stock to consultants (in shares)		415,167
Issuance of shares under Numoda Stock Purchase Agreement		$ 15,000	1,365,000			1,380,000
Issuance of shares under Numoda Stock Purchase Agreement (in shares)		15,000,000
Issuance of shares under JMJ Settlement Agreement		$ 8,077	1,061,923			1,070,000
Issuance of shares under JMJ Settlement Agreement (in shares)		8,076,923
Exchange of Bridge Notes			260,705			260,705
Common Stock issued to Socius		$ 24,059	1,780,501			1,804,559
Common Stock issued to Socius (in shares)		24,058,296
Net Loss as reported				(12,069,687)		(12,069,687)
Balance at Oct. 31, 2012		$ 394,804	$ 51,727,921	$ (47,601,427)	$ (10,484,022)	$ (5,962,724)
Balance (in shares) at Oct. 31, 2012	740	394,804,165

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended		128 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
OPERATING ACTIVITIES
Net Loss	$ (12,069,687)	$ (8,115,740)	$ (47,557,543)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	1,146,843	795,226	4,980,046
Amortization of deferred financing costs	78,824	0	338,824
Amortization of discount on convertible promissory notes	1,553,984	482,507	2,710,377
Impairment of intangible assets	0	0	26,087
Non-cash interest expense	2,844,456	4,106,212	11,494,012
(Gain) Loss on change in value of warrants and embedded derivative	(6,630,610)	(9,763,113)	(21,042,296)
Warrant Expense	150	557,935	764,360
Settlement Expense	265,000	0	265,000
Employee Stock Purchase Plan Expense	18,301	0	18,301
Value of penalty shares issued	0	0	149,276
Depreciation expense	13,776	28,406	209,448
Amortization expense of intangibles	148,002	132,288	742,642
Write off of intangible assets		33,211	33,211
Interest Income	0	267	267
Loss on note retirement	2,187,787	461,595	992,942
Change in operating assets and liabilities :
(Increase) decrease in prepaid expenses	11,676	1,037	(25,797)
decrease in grant receivable	0	244,479	0
(Increase) in other current assets	(5,961)	(2,221)	(8,182)
(Increase) in other assets	0	(38,438)	(132,271)
(Increase) decrease in deferred expenses	177,803	(1,146,783)	(694,572)
Increase in accounts payable and accrued expenses	5,719,172	3,123,302	12,504,260
(Decrease) increase in interest payable	29,779	94,547	(7,298)
Increase in deferred rent	(57,637)	62,441	4,803
Net cash used in operating activities	(4,568,344)	(8,942,842)	(34,234,103)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations		0	(44,940)
Purchase of property and equipment	(91,844)	0	(241,937)
Cost of intangible assets	(304,905)	(296,358)	(3,220,645)
Net cash used in Investing Activities	(396,749)	(296,358)	(3,507,522)
FINANCING ACTIVITIES
Proceeds from convertible notes	3,282,463	8,351,423	17,859,400
Repayment of convertible notes	(52,941)	(169,739)	(1,649,030)
(Increase) decrease in deferred offering expenses	(62,000)	(52,000)	(114,000)
Cash paid for deferred financing costs	0	(25,000)	(584,493)
Proceeds from notes payable	250,000	0	250,000
Proceeds from Officer Loan	74,500	295,000	1,444,485
Repayment of Officer Loan	(35,000)	(600,000)	(1,130,000)
Deferred Investment Funds	0		0
Net proceeds of issuance of Preferred Stock	0	1,342,672	8,610,499
Payment on cancellation of Warrants	0	0	(600,000)
Proceeds from the exercise of warrants	411,765	1,085,001	1,666,766
Net proceeds of issuance of Common Stock		0	11,988,230
Net cash provided by Financing Activities	3,868,787	10,227,357	37,741,857
Net increase (decrease) in cash	(1,096,306)	988,157	232
Cash at beginning of period	1,096,538	108,381	0
Cash at end of period	$ 232	$ 1,096,538	$ 232

Supplemental Disclosures of Cash Flow Information - USD ($)	12 Months Ended		128 Months Ended
	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Cash paid for Interest	$ 53,027	$ 148,392	$ 788,017
Supplemental Schedule of Noncash Investing and Financing Activities
Equipment acquired under notes payable	0	0	45,580
Common stock issued to Founders	0	0	40
Notes payable and accrued interest converted to Preferred Stock	0	0	15,969
Stock dividend on Preferred Stock	0	0	43,884
Accounts Payable from vendors settled in Common Stock	3,249,990	0	3,249,990
Accounts Payable from consultants settled with Common Stock	62,275	0	114,253
Notes payable and embedded derivative liabilities converted to Common Stock	9,324,971	4,149,114	15,160,221
Intangible assets acquired with notes payable	0	0	360,000
Intangible assets acquired with common stock	0	0	70,000
Debt discount in connection with recording the original value of the embedded derivative liability	306,568	3,505,605	6,473,385
Allocation of the original secured convertible debentures to warrants	0	0	214,950
Allocation of the warrants on convertible notes as debt discount	571,207	778,052	3,001,806
Cancellation of Note Receivable in connection with Preferred Stock Redemption	0	(3,051,000)	(3,051,000)
Note receivable in connection with exercise of warrants	0	2,389,500	9,998,210
Common stock issued in exchange for warrants	134,796	0	134,796
Warrants Issued in connection with issuance of Common Stock	517,797	0	2,023,347
Warrants Issued in connection with issuance of Preferred Stock	$ 0	$ 0	$ 3,587,625

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

12 Months Ended

Oct. 31, 2012

Nature Of Operations and Basis Of Presentation [Abstract]

Nature Of Operations and Basis Of Presentation [Text Block]

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis Inc. (the “Company”) is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Its platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations.

Since the Company’s inception in 2002, it has focused its initial development efforts upon immunotherapies targeting cervical cancer, its predecessor condition, cervical intraepithelial neoplasia, head and neck cancer, breast cancer, prostate cancer, and other cancers and infectious diseases. Although no products have been commercialized to date, research and development and investment continue to be placed behind the pipeline and the advancement of this technology. Pipeline development entails risk and expense. It is anticipated that ongoing operational costs for the Company will continue to increase significantly due to several ongoing clinical trials in this fiscal year.

Basis of Presentation

The preparation of financial statements in accordance with Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from estimates.

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets which raises substantial doubt about its ability to continue as a going concern. These losses are expected to continue for an extended period of time. The Company intends to continue raising funds through the sale of both debt and equity in order to continue funding ongoing clinical trials activity.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Subsequent to October 31, 2012, the Company successfully raised an aggregate of approximately $950,000 in additional capital through the sale of debt and equity securities.

The Company recognizes it will need to raise additional capital over and above the amount raised subsequent to October 31, 2012 in order to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Oct. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met; persuasive evidence of an arrangement exists, services have been rendered, the contract price is fixed or determinable, and collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple research grants. For the years ended October 31, 2012 and 2011, the Company did not receive any revenue from such grants.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of October 31, 2012 and 2011, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Property and Equipment

Property and equipment consists of laboratory equipment and is stated at cost. Depreciation and amortization is provided for on the straight-line basis over the estimated useful lives of the respective asset ranging from 3 to 5 years. Expenditures for maintenance and repairs that do not materially extend the useful lives of the respective assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations.

Intangible Assets

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective dates of the University of Pennsylvania (Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn and its patent attorneys.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets are recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued the Company would record an impairment of its estimated book value.

Deferred financing costs

The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized using the straight-line method over the shorter of (a) the term of the related debt or (b) the expected conversion date of the debt into equity instruments, which approximates the effective interest method. The amortization of deferred financing costs is included as a component of other expenses in the accompanying statements of operations. At October 31, 2012 and 2011, accumulated amortization totaled $89,976 and $11,152, respectively.

Net Loss Per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. For 2012 and 2011, approximately 55 million warrants and 49.4 million warrants, respectively (excluding approximately $25.6 million warrants, held by an affiliate of Optimus) include anti-dilutive provisions to adjust the number and price of the warrants based on certain types of equity transactions.

	As of October 31,
	2012		2011
Warrants		100,322,588		137,841,857
Stock Options		44,807,424		27,317,424
Convertible Debt (using the if-converted method)		33,919,264		61,660,382
Total		179,049,276		226,819,663

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, facilities and related overhead costs.

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Stock-based compensation for directors is reflected in general and administrative expenses in the statements of operations. Stock-based compensation for employees and consultants could be reflected in research and development expenses or general and administrative expenses in the statements of operations.

Fair Value of financial instruments

The carrying amounts of financial instruments, including cash, receivables, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Debt discount and amortization of debt discount

Debt discount represents the fair value of embedded conversion options of various convertible debt instruments and attached convertible equity instruments issued in connection with debt instruments. The debt discount is amortized over the earlier of (i) the term of the debt or (ii) conversion of the debt, using the straight-line method which approximates the interest method. The amortization of debt discount is included as a component of other expenses in the accompanying statements of operations.

Recent Accounting Pronouncements

In May 2011, FASB issued ASU No. 2011-04, Fair Value Measurements (ASC Topic 820). This ASU provides additional guidance on fair value disclosures. This guidance contains certain updates to the measurement guidance as well as enhanced disclosure requirements. The most significant change in disclosures is an expansion of the information required for “Level 3” measurements including enhanced disclosure for: (1) the valuation processes used by the reporting entity; and (2) the sensitivity of the fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. This guidance is effective for interim and annual periods beginning on or after December 15, 2011, with early adoption prohibited. Other than requiring additional disclosures on the Company’s “Level 3” disclosures, the adoption of this new guidance did not have a material impact on the Company’s consolidated results of operations and financial position.

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment." This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s financial position and results of operations.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and are subject to audit by tax authorities beginning with the year ended October 31, 2009.

Reclassification

Certain accounts in the prior year financial statements have been reclassified, for comparative purposes, in order to conform with the presentation in the current year financial statements. These reclassifications have no effect on the previously reported net loss.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

SHARE-BASED COMPENSATION EXPENSE

12 Months Ended

Oct. 31, 2012

Share-Based Compensation [Abstract]

Shareholders' Equity and Share-based Payments [Text Block]

3. SHARE-BASED COMPENSATION EXPENSE

The Company adopted ASC 718 and used the modified prospective transition method, which requires the application of the accounting standard as of November 1, 2005, the first day of the Company’s fiscal year 2006. In accordance with the modified prospective transition method, the Company’s Financial Statements for prior periods were not restated to reflect, and do not include the impact of ASC 718. The Company began recognizing expense in an amount equal to the fair value of share-based payments (stock option awards) on their date of grant, over the requisite service period of the awards (usually the vesting period). Under the modified prospective method, compensation expense for the Company is recognized for all share based payments granted and vested on or after November 1, 2005 and all awards granted to employees prior to November 1, 2005 that were unvested on that date but vested in the period over the requisite service periods in the Company’s Statement of Operations. Prior to the adoption of the fair value method, the Company accounted for stock-based compensation to employees under the intrinsic value method of accounting set forth in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees , and related interpretations. Therefore, compensation expense related to employee stock options was not reflected in operating expenses in any period prior to the fiscal year of 2006 and prior period results have not been restated. Since the date of inception to October 31, 2005 had the Company adopted the fair value based method of accounting for stock-based employee compensation under the provisions of ASC 718, Stock Compensation expense would have totaled $328,176 and the effect on the Company’s net loss would have been as follows for the period March 1, 2002 (date of inception) to October 31, 2012:

	March 1, 2002 (date of inception) to October 31, 2012
Net Loss as reported	$	(47,557,543	)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176	)
Adjusted Net Loss	$	(47,796,502	)

PROPERTY AND EQUIPMENT

12 Months Ended

Oct. 31, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

4. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	October 31, 2012			October 31, 2011
Laboratory Equipment	$	287,518		$	195,672
Accumulated Depreciation		(209,450	)		(195,672	)
Net Property and Equipment	$	78,068		$	-

Depreciation expense for the years ended October 31, 2012 and 2011 and the period from March 1, 2002 (inception) to October 31, 2012 was $13,776, $28,406 and $209,450, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

INTANGIBLE ASSETS

12 Months Ended

Oct. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

5. INTANGIBLE ASSETS

Under the Penn license agreements we are billed actual patent expenses as they are passed through from Penn and or billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31, 2012			October 31, 2011
License	$	651,992		$	651,992
Patents		2,422,409			2,117,505
Total intangibles		3,074,401			2,769,497
Accumulated Amortization		(660,646	)		(512,645	)
Intangible Assets	$	2,413,755		$	2,256,852

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. During the fiscal year ended October 31, 2011, the Company wrote off approximately $33,000 in capitalized patent costs related to four patent applications that had expired or were abandoned. No patent applications with future value were abandoned or expired and charged to expense in the current year. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $148,002, $132,288 and $742,642 for the years ended October 31, 2012 and 2011 and for the period from March 1, 2002 (inception) to October 31, 2012, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013			140,000
2014			140,000
2015			140,000
2016			140,000
2017			140,000

ACCRUED EXPENSES:

12 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

6. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	October 31, 2012		October 31, 2011
Salaries and other compensation	$	774,001	$	531,040
Clinical Trial		56,468		2,358,248
Vendors		77,512		-
Consultants		32,200		32,200
Financing costs		174,970		-
Legal		214,902		46,346
Interest Payable		28,859		-
Other		8,500		8,500
	$	1,367,412	$	2,976,334

CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE

12 Months Ended

Oct. 31, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

7. CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE

Convertible Notes payable consist of the following:

	October 31, 2012		October 31, 2011
May 2011 Note Financing	$	—	$	3,392,158
October 2011 Note Financing		58,824		1,341,738
December 2011 Note Financing		131,928		—
May 2012 Note Financing		588,313		—
Bridge Notes		185,758		711,701
JMJ Financial		73,590		570,802
Hanover Holdings Note		362,791		—
Magna		333,086		—
Chris French		25,950		—
Asher		150,687		—
Yvonne Paterson		103,804		—
James Patton		78,909		—

Total Convertible Notes		2,093,640		6,016,399

Unamortized discount	(4,541	)	(1,300,345	)

Derivative Liability	—		946,046

	2,089,099		5,662,100

Current Portion of Convertible Notes		2,089,099		5,091,298

Long-term Convertible Notes less current portion	$	—	$	570,802

May 2011 Note Financing

On May 9, 2011, we entered into a Note Purchase Agreement with certain accredited investors, whereby the investors acquired approximately $7.1 million of our convertible promissory notes, which we refer to as the May 2011 Notes, for an aggregate purchase price of approximately $6.0 million in a private placement.

The May 2011 Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of May 2011 Notes purchased at the closing on May 12, 2011. The May 2011 Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2011 Note at an exercise price of $0.15 per share.

The May 2011 Notes mature on May 12, 2012. We may redeem the May 2011 Notes, at the option of the Company only, under certain circumstances. The warrants are exercisable at any time on or before May 12, 2014. The warrants may be exercised on a cashless basis under certain circumstances. To the extent an investor does not elect to convert its May 2011 Notes as described above, the principal amount not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The May 2011 Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided, only 85% of the initial principal amount of each May 2011 Note is convertible prior to maturity. The May 2011 Notes and warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the May 2011 Notes or exercise any of the warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate charge of $4,905,842 at the date of issuance.

During the twelve months ended October 31, 2011, the Company converted approximately $1,897,000 in principal into 12,647,077 shares of the Company’s common stock at a conversion price of $0.15. During the twelve months ended October 31, 2012, the Company converted approximately $1,962,060 in principal into 13,080,393 shares of the Company’s common stock at a conversion price of $0.15, recording non-cash expense of approximately $ 318,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $3.2 million in remaining outstanding principal on the May 2011 Notes, pursuant to which such holders received an aggregate of approximately 37.6 million shares of Common Stock and warrants to purchase an aggregate of approximately 3.6 million shares of Common Stock in exchange for surrendering or converting the Existing May 2011Notes and surrendering warrants to purchase an aggregate of approximately 22.4 million shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $1.3 million resulting from this exchange. As of October 31, 2012, there was no remaining principal outstanding under the May 2011 Notes.

Accretion of the discount was $1,788,718 and $3,117,123 for the years ended October 31, 2012 and 2011 respectively.

October 2011 Note Financing

On October 28, 2011, we entered into a Note Purchase Agreement, which we refer to as the October 2011 Notes, with certain accredited investors, including Thomas A. Moore, our Chairman and Chief Executive Officer, and Mark J. Rosenblum, our Chief Financial Officer, (Mr. Rosenblum acquired a note in the principal amount of approximately $59,000 for an aggregate purchase price of $50,000) whereby the investors acquired approximately $2.3 million of our convertible promissory notes, which we refer to as the Notes, for an aggregate purchase price of approximately $2.0 million in a private placement, which we refer to as the October 2011 offering. The Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the October 2011 offering, which took place on October 31, 2011. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $0.15 per share. The Notes purchased in the October 2011 offering were paid for in cash or, with respect to Notes acquired by Mr. Moore, in exchange for the cancellation of $400,000 of outstanding indebtedness owed by us to Mr. Moore.

The Notes mature on October 31, 2012. Subsequent to October 31, 2012, the remaining outstanding note was assigned to Magna (see Footnote 16: Subsequent Events, Other Hanover-Related Transactions). We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before October 31, 2014. The Warrants may be exercised on a cashless basis under certain circumstances.

To the extent an investor does not elect to convert its Notes as described above, the principal amount of the Notes not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided in the Notes, only 85% of the initial principal amount of each Note is convertible prior to maturity. The Notes and Warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the Notes or exercise any of the Warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

In connection with the October 2011 offering, we entered into a Registration Rights Agreement, dated as of October 28, 2011 with the investors. Pursuant to such agreement, we agreed with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and filed a registration statement to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants which became effective on November 23, 2011.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate change of $987,439 at the date of issuance.

During the year ended October 31, 2012, the Company converted approximately $1.2 million in principal into 8,183,333 shares of the Company’s common stock at a conversion price of $0.15, recording non-cash expense of approximately $ 296,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $1.0 million in outstanding principal on the October 2011 Notes, pursuant to which such holders received an aggregate of approximately 12.1 million shares of Common Stock and warrants to purchase an aggregate of approximately 1.3 million shares of Common Stock in exchange for surrendering or converting the Existing October 2011 Notes and surrendering warrants to purchase an aggregate of approximately 6.0 million shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $530,000 resulting from this exchange.

Accretion of the discount was $984,733 and $2,705 for the years ended October 31, 2012 and 2011 respectively. The outstanding principal balance was $54,824 at October 31, 2012.

December 2011 Note Financing

On December 29, 2011, we entered into a Note Purchase Agreement, which we refer to as the December 2011 Notes, with certain accredited investors, whereby the investors acquired approximately $1,232,000 million of our convertible promissory notes for an aggregate purchase price of approximately $1.0 million in a private placement, which we refer to as the December 2011 offering. The December 2011 Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the December 2011 offering. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $0.15. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $0.15 per share.

The Notes mature on January 9, 2013. We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before January 9, 2015. The Warrants may be exercised on a cashless basis under certain circumstances.

In connection with the December 2011 offering, we entered into a Registration Rights Agreement with the investors. Pursuant to such agreement, we agreed with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and agreed to file a registration statement to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants. The registration statement was filed on January 27, 2012.

Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with each of the May, October and December 2011 offerings and received compensation of cash placement fees equal to amounts ranging from 6% to 7% of the aggregate purchase price paid by investors and Warrants to purchase 3,328,625 shares of our common stock (approximately 4% of the shares of our common stock issuable upon conversion of all the Notes), which warrants are exercisable at $0.15 per share and shall expire on dates ranging from May 12, 2014 to January 9, 2015.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate charge of $586,376 at the date of issuance.

During the year ended October 31, 2012, the Company converted approximately $828,000 in principal into 5,516,666 shares of the Company’s common stock at a conversion price of $0.15, recording non-cash expense of approximately $ 205,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $215,000 in outstanding principal on the December 2011 Notes, pursuant to which such holders received an aggregate of approximately 2.5 million shares of Common Stock and warrants to purchase an aggregate of approximately 1.3 million shares of Common Stock in exchange for surrendering or converting the Existing December 2011 Notes and surrendering warrants to purchase an aggregate of approximately 2.9 million shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $100,000 resulting from this exchange. In October 2012, $31,284 of principal was assigned pursuant to the terms of an assignment agreement with Magna Group, LLC.

Accretion of the discount was $559,480 for the year ended October 31, 2012. The outstanding principal balance, at October 31, 2012 was $158,824. On the balance sheet, the December 2011 Notes were recorded at $131,928 ($158,824 net of debt discount of $28,896). Subsequent to October, 31, 2012, the remaining outstanding note was assigned to Magna (see Footnote 16: Subsequent Events, Other Hanover-Related Transactions.)

May 2012 Note Financings

Effective May 14, 2012, we entered into a Note Purchase Agreement with certain accredited investors, whereby the investors acquired $953,333 of our convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash which represented an original issue discount of 25%. The May 2012 Notes are convertible into shares of our common stock at $0.15 per share. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2012 Notes at an exercise price of $0.15 per share. The Notes and Warrants also provide that on December 1, 2012, solely to the extent the conversion price of the Notes or the exercise price of the Warrants, as applicable, is less than the “Market Price” (as defined in the Notes or the Warrants, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The May 2012 Notes mature on May 18, 2013. We may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances and expire on May 18, 2017.

The Company elected to apply the fair-value option to account for the May 2012 notes and have recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the notes which amounted to $133,634 for the period from the date of issuance or May, 14, 2012 through October 31, 2012 were recognized as a noncash expense.

In addition, as a result of the reset provisions discussed above, the warrants which have been recorded at a fair value of $291,400 on May 14, 2012 are being reflected as a warrant liability as of the date of issuance. As of October 31, 2012, the warrant liability amounted to $112,487 which resulted in a noncash income of approximately $178,913 for the year ended October 31, 2012.

Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with the May 2012 offering and received compensation of a cash placement fee equal to 7% of the aggregate purchase price paid by investors (Rodman raised $400,000 of the total purchase price of $715,000) in the May 2012 offering amounting to $28,000 and warrants to purchase 355,556 shares of our common stock, which warrants are exercisable at $0.15 per share and shall expire on May 18, 2017.

Senior Convertible Promissory Notes

Effective June 18, 2009, the Company entered into a Note Purchase Agreement with certain accredited investors, pursuant to which such investors acquired senior convertible promissory notes of the Company. At July 31, 2011, the Company had one outstanding senior convertible promissory note with $88,824 in principal value and $26,471 in accrued interest remaining. On August 19, 2011, the Company issued 768,633 shares of common stock to this investor in full satisfaction of this senior convertible promissory note. As of October 31, 2011, the Company had no remaining senior convertible promissory notes outstanding.

Junior Subordinated Convertible Promissory Notes

We refer to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in our Bridge Notes, each Investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of Warrant. As of October 31, 2012, substantially all of the Bridge Warrants have an exercise price of $0.15 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the Maturity Date. The warrants may be exercised on a cashless basis under certain circumstances.

During the twelve month period ended October 31, 2011, the Company reached agreement with ten investors, whose notes were to mature on dates ranging from December 31, 2010 to April 30, 2011, in the aggregate principal value of approximately $479,000 (included in the above aggregate principal value of $1,886,851) to exchange their original notes for new notes due on dates ranging from March 31, 2011 to August 2, 2011. In return for exchanging their notes, these investors received additional interest of $25,208 plus approximately 816,000 additional warrants, valued using the BSM model (which approximates the Lattice Model), at approximately $87,000.

During the twelve month period ended October 31, 2011,the Company reached agreement with three investors, whose notes were to mature on dates ranging between August 1 and October 31, 2011,in the aggregate principal value of approximately$318,000 (included in the above aggregate principal value of $1,886,851) to make partial repayments on their notes totaling $99,000 and exchanged the remaining principal on the original notes for new notes (with the same amount of principal) due on dates ranging from March 31, 2012 to May 31, 2012. These three investors also received approximately 730,000 additional warrants, at a fair value totaling approximately $80,000.

The Company accounted for two of these three note exchanges as substantial debt modifications under ASC 470-50: Debt Modifications and Extinguishments . Therefore, the Company recorded the present values of the principal on the new notes along with the fair value of the additional warrants issued and wrote off the remaining principal on the old notes. The Company then recorded a loss on exchange of approximately $22,000 (other income/(expense)) for the difference between (1) the sum of the remaining principal on the old notes and (2) the sum of the present values of the principal on the new notes and the fair value of the additional warrants. For the third investor, the Company recorded approximately $27,000 to equity (included in the above fair value of $80,000), representing the fair value of the additional warrants issued upon exchange of their note.

During the twelve month period ended October 31, 2011, the Company repaid approximately $530,000 in principal and interest. In addition, the Company converted approximately $1.3 million of principal and interest on these outstanding junior subordinated convertible promissory notes into 8,652,737 shares of the Company’s common stock at a conversion price of $0.15 per share.

As of October 31, 2011, the Company had approximately $756,000(in principal to be repaid to investors) in outstanding junior subordinated convertible promissory notes with Original Issue Discount (“OID”) amounts ranging from 10% to 15% and with maturity dates ranging from October 19, 2011 to May 12, 2012. These junior unsubordinated notes were recorded on the balance sheet, at October 31, 2011, at $711,701 (remaining principal of $756,000 net of debt discount of approximately $45,000).

During the year ended October 31, 2012, the Company entered into an exchange agreement with an accredited investor in which the investor exchanged a convertible promissory note in the aggregate principal amount of $300,000 for (i) a convertible promissory note in the aggregate principal amount $352,941 and in substantially the same form as the existing note except with a maturity date of June 30, 2012 and (ii) a warrant to purchase up to 2,352,940 shares of common stock at an exercise price of $0.15 per share. The warrants expire in February 2015. The Company recorded noncash expense of approximately $247,000 to the loss on note retirement account resulting from this exchange for the year ended October 31, 2012. In October 2012, this note was assigned to Magna (see Magna Note disclosure in this footnote).

During the year ended October 31, 2012, the Company paid approximately $53,000 in principal on its Bridge Notes. In addition, the Company converted approximately $169,000 of principal on these Bridge Notes into 1,126,667 shares of the Company’s common stock at a conversion price of $0.15 per share. The Company recorded noncash expense of approximately $27,000 to the gain on note retirement account resulting from these conversions.

As of October 31, 2012, the Company had approximately $186,000 in principal outstanding on its junior subordinated convertible promissory notes with maturity dates ranging from October 19, 2011 to May 12, 2012.

JMJ Financial

On October 31, 2011, the Company held two notes from JMJ Financial in the aggregate principal amount of $660,000. These notes bear interest at a rate of 8% per annum. Due to the conversion feature into a variable number of shares, these notes are valued at fair value each reporting period. At October 31, 2011, the fair value of these notes was $570,802. These notes were classified as long-term convertible notes at October 31, 2011 as they had maturity dates in April 2014.

In November and December, 2011, the Company converted $500,000 of the aggregate principal amount of $660,000 into 3,600,000 shares of common stock. As a result, the Company recorded a noncash income of approximately $36,000 related to the conversion of these notes to equity.

On May 8, 2012, the Company entered into a Settlement Agreement (the “ Settlement Agreement ”) with JMJ Financial which provides for (i) an additional borrowing by the Company of $500,000 from JMJ Financial on the principal amount outstanding under one of the notes issued by JMJ to the Company in April 2011, (ii) the cancellation of all of the outstanding notes issued by JMJ to the Company in April 2011, (iii) the cancellation of all of the outstanding notes issued by the Company to JMJ in April 2011, other than the portion of such notes for which JMJ has paid cash to the Company, (iv) a mutual release of any claims held by the Company or JMJ relating to an outstanding dispute and (v) the issuance by the Company of 4,000,000 newly issued shares of the Company’s common stock (the “ Settlement Shares ”) to JMJ as consideration for the cancellation of the notes and the release. As a result of the Settlement Agreement, no further payments will be made by either the Company or JMJ under the notes issued by each party in April 2011. The Company recorded noncash expense of approximately $805,000 for the issuance of the Settlement Shares to JMJ under the Settlement Agreement and recognition of a beneficial conversion feature, resulting from the issuance of shares.

During the year ended October 31, 2012, the Company converted the remaining notes outstanding totaling $660,000 into 4,725,927 shares of the Company’s common stock. The Company recorded noncash income of approximately $250,000 upon conversion.

On August 27, 2012, in a private placement pursuant to a note purchase agreement, we issued JMJ Financial a one year convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000 ,. The August 2012 Note is initially convertible at a per share conversion price equal to $0.15. In addition, if the August 2012 Note is converted after November 30, 2012 and the market price of our common stock is less than $0.16 per share on the date of conversion, then the conversion price shall equal 95% of the arithmetic average of the three lowest closing trading prices for the common stock during the 15 trading day period ending on the latest complete trading day prior to the applicable conversion date. Pursuant to the terms of the August 2012 Note, we agreed to register with the SEC up to 3,250,000 shares of our common stock which may be issuable upon conversion of the August 2012 Note. These shares were registered on August 31, 2012.

On August 27, 2012, we entered into a settlement agreement with JMJ Financial pursuant to which we issued to JMJ Financial 4,076,923 shares of our common stock for the mutual release of any claims held by our company or JMJ Financial relating to our failure to file the registration statement related to the May 2012 issuance of 4,000,000 shares of our common stock to JMJ Financial and have the registration statement declared effective by certain prescribed deadlines.

As of October 31, 2012, the August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares this note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the note was $73,590. Because this note matures within one year, it has been classified as a current liability on the balance sheet at October 31, 2012.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which we refer to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which we refer to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note we refer to as the Hanover PIPE Notes. The Hanover PIPE Notes bear interest at a rate of 12%, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover PIPE Notes. The Hanover PIPE Notes are convertible into shares of our Common Stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Hanover PIPE Notes mature eight months from their respective issuance dates. To the extent Hanover does not elect to convert the Hanover PIPE Notes as described above, the principal amount and interest of such Hanover PIPE Notes shall be payable in cash at maturity. The Hanover PIPE Notes may be converted at any time by Hanover, at its option, in whole or in part. The Hanover PIPE Notes include a limitation on conversion, which provides that at no time will Hanover be entitled to convert any portion of the Hanover PIPE Notes, to the extent that after such conversion, Hanover (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

Unrealized losses on the mark-to-market of the notes which amounted to $97,791, for the period from the dates of issuance (September 19 and October 19, 2012) were recorded as non-cash expense.

Magna note

In October 2012, pursuant to the terms of various Assignment Agreements, which we refer to as the Assignment Agreements, Magna Group, LLC, an affiliate of Hanover, which we refer to as Magna, acquired $400,076 in aggregate principal amount of our outstanding convertible notes from certain third parties and entered into agreements to acquire an additional $340,523 in aggregate principal amount of our outstanding convertible notes from other third parties. Pursuant to the terms of such Assignment Agreements, we delivered two convertible notes to Magna in an aggregate principal amount of $740,599, in anticipation of the closing of all of the transactions contemplated by such Assignment Agreements. On October 25, 2012, the convertible note in the aggregate principal amount of $617,723 previously delivered to Magna was exchanged for a new convertible note in the aggregate principal amount of $400,076, convertible into shares of Common Stock, which we refer to as the Magna Exchange Note, to reflect such portion of the convertible notes actually issued as of October 25, 2012 pursuant to the Assignment Agreements, and the remaining convertible note in the aggregate principal amount of $122,876 previously delivered to Magna was returned to us and cancelled. The Magna Exchange Note bears interest at a rate of 6%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Magna Exchange Note. The Magna Exchange Note is convertible into shares of our Common Stock at a conversion price equal to 73% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the lowest complete trading day prior to the applicable conversion date. The Magna Exchange Note matures on October 17, 2013. To the extent Magna does not elect to convert the Magna Exchange Note as described above, the principal amount and interest of the Magna Exchange Note shall be payable in cash at maturity. Upon the closing of the remaining transactions contemplated by such applicable Assignment Agreements, we are obligated to issue additional convertible notes in the form of the Magna Exchange Note with respect to the outstanding $340,523 in aggregate principal amount of convertible notes held by the third party signatories to the other Assignment Agreements, which we anticipate to occur during the fourth quarter of 2012.

The Magna Exchange Note may be converted at any time by Magna, at its option, in whole or in part. The Magna Exchange Note includes a limitation on conversion, which provides that at no time will Magna be entitled to convert any portion of the Magna Exchange Note, to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

As of October 31, 2012, Magna had converted approximately $0.1 million in principal into 2,522,119 shares of our common stock at prices ranging from $0.035624-$0.0412, which resulted in non-cash expense of approximately $13,500 for the period ended October 31, 2012. Unrealized losses on the mark-to-market of the note which amounted to $33,011, for the period from the date of issuance (October 17, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Asher

On September 11, 2012, in a private placement pursuant to a note purchase agreement, we issued Asher Enterprises, Inc, which we refer to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which we refer to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of our Common Stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matures on June 13, 2013, nine months from its issuance date. The Asher Note may be converted by Asher, at its option, in whole or in part. The Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

Unrealized losses on the mark-to-market of the note which amounted to $47,187, for the period from the date of issuance (September 11, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Chris French

On September 27, 2012, in a private placement pursuant to a note purchase agreement, we issued our employee Christine French a convertible promissory note in the aggregate principal amount of $25,000, for a purchase price of $25,000, which we refer to as the French Note. The French Note bears interest at a rate of 12%, compounded annually. The French Note is convertible into shares of our Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The French Note matures one month from its issuance date. Additionally, Ms. French will receive a warrant, which we refer to as the French Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the French Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The French Warrant may be exercised on a cashless basis under certain circumstances. The French Note and the French Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Ms. French be entitled to convert any portion of the French Note or French Warrant, to the extent that after such conversion or exercise, as applicable, Ms. French (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants to be issued upon future conversion of the note were recorded as a warrant liability, at October 31, 2012, at a fair value of $4,565 at the date of issuance. Unrealized losses on the mark-to-market of the note which amounted to $5,515, for the period from the date of issuance (September 27, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Yvonne Paterson

On September 25, 2012, in a private placement pursuant to a note purchase agreement, we issued our affiliate Dr. Yvonne Paterson a convertible promissory note in the aggregate principal amount of $100,000, for a purchase price of $100,000, which we refer to as the Paterson Note. The Paterson Note bears interest at a rate of 12%, compounded annually. The Paterson Note is convertible into shares of our Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Paterson Note matures one month from its issuance date. Additionally, Dr. Paterson will receive a warrant, which we refer to as the Paterson Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the Patterson Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The Paterson Warrant may be exercised on a cashless basis under certain circumstances. The Paterson Note and the Paterson Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Paterson be entitled to convert any portion of the Paterson Note or Paterson Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Paterson (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants to be issued upon future conversion of the note were recorded as a warrant liability, at October 31, 2012, at a fair value of $18,258 at the date of issuance. Unrealized losses on the mark-to-market of the note which amounted to $22,062, for the period from the date of issuance (September 27, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

James Patton

On August 2, 2012, in a private placement pursuant to a note purchase agreement, we issued Dr. James Patton, a member of our board of directors, a convertible promissory note, which we refer to as the Patton Note, in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of our Common Stock at a per share conversion price equal to $0.15. Additionally, Dr. Patton received a warrant, which we refer to as the Patton Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the Patton Note at an exercise price of $0.15 per share. The Patton Note and Patton Warrant also provide that on December 1, 2012, solely to the extent the conversion price of the Patton Note or the exercise price of the Patton Warrant, as applicable, is less than the Market Price (as defined in the Patton Note or the Patton Warrant, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The Patton Note matures on August 2, 2013. We may redeem the Patton Note under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017. The Patton Warrant may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants issued were recorded as a warrant liability, at the date of issuance, at a fair value of $13,311 at the date of issuance. The company recorded non-cash income from a decline in the fair value of the warrant liability, at October 31, 2012, of $5,200, Unrealized losses on the mark-to-market of the note which amounted to $38,944, for the period from the date of issuance (August 2, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Accretion of the discount amounted to $3,277, for the period ended October 31, 2012.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

NOTES PAYABLE-OFFICER:

12 Months Ended

Oct. 31, 2012

Notes Payable Officer [Abstract]

Notes Payable Officer [Text Block]

8. NOTES PAYABLE-OFFICER:

Moore Notes

The Company has agreed to sell senior promissory notes to Mr. Moore, our chief executive officer, from time to time (“the Moore Notes”). These notes bear interest at the rate of 12% per annum. Currently, under the terms of the amended and restated Moore Notes: (i) the maturity date is the earlier of the date of consummation of an equity financing in an amount of $6.0 million or more or the occurrence of any event of default as defined in the Moore Notes. As of October 31, 2011, the Company owed Mr. Moore, our chief executive officer, approximately $408,000 in principal and interest under the Moore Notes.

For the twelve months ended October 31, 2012, Mr. Moore loaned the Company $74,500 under the Moore Notes. The Company paid Mr. Moore $35,000 in principal on the Moore Notes. For the year ended October 31, 2012 and 2011 and the period from inception, the Company recorded interest expense of $29,695 and $78,077 and $300,022 respectively. As of October 31, 2012 and October 31, 2011, respectively, the Company was not in default under the terms of the Moore Agreement. The Company intends to repay Mr. Moore when funds are sufficiently available. As of October 31, 2012, the Company owed Mr. Moore approximately $477,000 in principal and interest under the Moore Notes.

NOTES PAYABLE-OTHER:

12 Months Ended

Oct. 31, 2012

Other Notes Payable [Abstract]

Other Notes Payable [Text Block]

9. NOTES PAYABLE-OTHER:

On July 21, 2012, the Company received $250,000 from an accredited investor in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and matures on December 31, 2012 (“July 2012 Note”). This note currently still remains outstanding. The Company has recorded approximately $23,000 in interest related to this promissory note, through October 31, 2012. We are currently negotiating conversion of this note into shares of common stock.

DERIVATIVES

12 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

10. DERIVATIVES

The table below lists the Company’s derivative instruments as of October 31, 2012 and 2011:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Total Valuation at October 31, 2010	$	777,154		$	21,937		$	13,006,194		$	81,028
Issuance of November 2010 Bridge Notes		931,579			96,579			391,076			150,156
Exchange of November 2010 Bridge Notes		17,175			17,175			86,963			9,389
Issuance of January 2011 Bridge Notes		452,941			57,941			173,808			41,024
Note Payoffs		(187,582	)
Issuance of Warrants								35,523
Accreted Interest					(73,363	)
Exercise of Warrants								(1,382,847	)
Change in FV								(3,789,889	)		(51,972	)
Total Valuation at January 31, 2011		1,991,267			120,269			8,520,828			229,625

Issuance of Q2 2011 Bridge Notes		473,392			43,392			121,238			71,336
Issuance of Long-term Convertible Promissory Notes		626,400									-
Note Payoffs		(159,675	)								(5,904	)
Issuance of Warrants								2,990,520
Accreted Interest					(74,422	)
Exercise of Warrants								(639,960	)
Change in FV								4,915,676			763,523
Total Valuation at April 30, 2011	$	2,931,384		$	89,239		$	15,908,302		$	1,058,580

Issuance of Q3 2011 Bridge Notes		11,765			1,765			4,968			5,051
Issuance of May 2011 Notes		7,077,936			1,553,254			-			2,719,345
Note Payoffs		(26,316	)								(8,860	)
Additional warrants issued to Bridge Note holder								36,376
Exchange of Bridge Notes		8,033			8,033						2,656
Conversion of Bridge Notes		(1,164,947	)								(381,209	)
Conversion of May 2011 Notes		(671,500	)								(166,980	)
Exchanges/Exercises of October 2007 Warrants								(1,186,959	)
Accreted Interest					(340,050	)
Change in FV								(6,826,019	)		(2,141,984	)
Total Valuation at July 31, 2011	$	8,166,355			1,312,241			7,936,668			1,086,599
Issuance of October 2011 Notes		2,326,471			459,396			-			396,818
Note Payoffs		(155,806	)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788	)								(10,530	)
Conversion of May 2011 Notes		(1,225,561	)								(110,494	)
Reclassification of Warrant liability to Equity								(186,908	)
Exchange of Warrants								816,259
Accreted Interest					(471,290	)
Change in FV								(2,174,948	)		(416,347	)
Total Valuation at October 31, 2011	$	8,976,071			1,300,347			6,391,071			946,046
Issuance of December 2011 Notes		1,232,353			258,178			-			306,568
Conversion of Bridge Notes		(169,000	)								-
Conversion of May 2011 Notes		(1,924,060	)								(341,342	)
Conversion of October 2011 Notes		(1,227,500	)								(329,433	)
Partial Note Repayments		(52,941	)
Conversion of Long-term Convertible Promissory Notes		(540,000	)
Exchange of Warrants								59,572
Accreted Interest					(532,559	)
Change in FV								(923,052	)		159,657
Total Valuation at January 31, 2012	$	6,294,923		$	1,025,966		$	5,527,591		$	741,496
Exchange of Bridge Notes		52,941						-
Conversion of May 2011 Notes		(38,000	)								(5,016	)
Conversion of December 2011 Notes		(827,500	)								(160,677	)
Exchange of Warrants								(134,796	)
Accreted Interest					(569,419	)
Change in FV								(2,302,707	)		(438,054	)
Total Valuation at April 30, 2012	$	5,482,364		$	456,547		$	3,090,088		$	137,749
Issuance of May 2012 Notes		953,333						291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673	)		(200,632	)					(115,046	)
Debt for Equity Exchange: Bridge Notes		(50,000	)					(4,750	)
July 2012Exchange of Warrants								(407,501	)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800	)
Accreted Interest					(229,392	)
Change in FV								(1,703,252	)		(20,567	)
Total Valuation at July 31, 2012	$	1,739,224			26,523			1,265,985			2,136
Issuance of Patton Note		66,667						13,311
Issuance of French Note		25,000						4,565
Issuance of Paterson Note		100,000						18,258
Issuance of Hanover September Note		132,500
Issuance of Asher Note		103,500
Issuance of Hanover October Note		132,500
Issuance of JMJ Note		100,000
Assignment of Notes to Magna		(384,264	)
New Magna Note (result of above assignment)		400,075
Magna Conversions		(100,000	)
Accreted Interest					(21,984	)
Additional warrants issued due to investors due to anti-dilution provision								150
Change in FV								(868,133	)		(2,136	)
Total Valuation at October 31, 2012	$	2,315,202			4,541			434,136			-

Warrants

As of October 31, 2012, there were outstanding warrants to purchase 100,322,588 shares of our common stock with exercise prices ranging from $0.053 to $0.17 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing

Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1495-0.17		24,754,595	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	0.0530-0.15			1,410,938	October 2015-August 2017	August – September 2012 Convertible Promissory Notes

		Subtotal:		74,762,588
Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
	Grand Total			100,322,588

(1)

During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

As of October 31, 2011, there were outstanding warrants to purchase 137,841,857 shares of our common stock with exercise prices ranging from $0.15 to $0.1952 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	0.15		47,090,487	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		287,001	August 2012	August 2007 Notes
Common Stock Purchase Warrant	$	0.15		23,593,122	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		7,754,902	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15 - $0.17		22,630,101	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		7,674,512	August 2014	Executive Officer
Common Stock Purchase Warrant	$	0.15-$0.1952		446,956	February 2012	Vendor & Other
Common Stock Purchase Warrant	$	0.15		2,804,776	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
	Subtotal			112,281,857

Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Optimus Preferred Stock Agreement (4/04/2011)
	Grand Total			137,841,857

(1)

At October 31, 2012, the Company had approximately 15.1 million of its total 100.3 million outstanding warrants classified as equity (equity warrants). At October 31, 2011, the Company had approximately 36.8 million of its total 137.8 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the stockholders equity section of the balance sheet. Our equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

At October 31, 2012, the Company had approximately 85.2 million of its total 100.3 million outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2012 was approximately $.4 million At October 31, 2011 the Company had approximately 101 million of its total 137.8 million outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2011, was approximately $6.39 million. In fair valuing the warrant liability, at October 31, 2012 and October 31, 2011, the Company used the following inputs in its BSM Model:

	10/31/2012		10/31/2011

Exercise Price:		0.053-0.17		0.15-0.17

Stock Price		0.045		0.141

Expected term:		81-1736 days		289-1219 days

Volatility %		66.51%-146.78%		60.23%-163.40%

Risk Free Rate:		.09%-.72%		.09-.56%

Warrant Liability/Embedded Derivative Liability

Warrant Liability

As of October 31, 2012, the Company had approximately 85.2 million of its total approximately 100.3 million total warrants classified as liabilities (liability warrants). Of these 85.2 million liability warrants, approximately 50.4 million warrants are outstanding and 34.8 million warrants are exchange warrants – nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 13.1 million of our 85.2 million liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

As of October 31, 2011, the Company had approximately 101 million of its total approximately 137.8 million total warrants classified as liabilities (liability warrants). The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 49.4 million of our 101 million liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At October 31, 2012 and 2011, the fair value of the warrant liability was approximately $434,000 and $6,391,000, respectively. For the twelve months ended October 31, 2012 and October 31, 2011, the Company reported income of approximately $6.4 million and $7.8 million, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the twelve months ended October 31, 2012, investors in the Company exercised 2,745,097 warrants at a price of $0.15 per share, resulting in total proceeds to the Company of approximately $412,000. During the twelve months ended October 31, 2011, the Company exercised 7,233,341 warrants at a price of $0.15 per share, resulting in total proceeds to the Company of $1,085,001.

2011 Warrant Exchange

In addition, in an effort to reduce the number of the warrants outstanding from the October 17, 2007 private placement by the Company, the Company has entered into exchange agreements with certain of the holders of such warrants pursuant to which such holders received shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and/or warrants to purchase shares of Common Stock in amounts that were determined in such negotiations.

During the twelve months ended October 31, 2012, the Company exchanged October 2007 warrants to purchase 4,791,337 shares of Common Stock for new warrants to purchase 6,388,449 shares of Common Stock. The new warrants issued pursuant to the exchanges are identical to the October 2007 warrants, except that such warrants do not contain any economic anti-dilution adjustment. The Company recorded noncash expense of approximately $25,000 to the changes in fair value account resulting from this exchange. Subsequently, the Company exchanged these new warrants, in the amount of 6,388,449 for shares of our common stock in the amount of 1,597,112. The Company recorded noncash income of approximately $54,000 due to the changes in fair value at the date of exchange and a noncash expense of approximately $89,000 resulting from this exchange of warrants for shares of our common stock during the twelve months ended October 31, 2012.

July 2012 Warrant Exchange

On June 8, 2012, Thomas A. Moore, our Chief Executive Officer, waived our obligation to keep reserved from our authorized and available shares of common stock, such number of shares of our common stock necessary to effect the exercise or conversion, as applicable, in full, of (i) warrants to purchase an aggregate of 11,064,611 shares of our common stock and (ii) promissory notes convertible into 800,000 shares of our common stock. This waiver expired on August 16, 2012, the date that we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock.

On July 5, 2012, in consideration for the waiver described above, we entered into an exchange agreement with Mr. Moore, with an effective date of June 8, 2012, pursuant to which Mr. Moore surrendered warrants to purchase an aggregate of approximately 11,064,611 shares of our common stock to us in exchange for receiving warrants to purchase an aggregate of approximately 11,064,611 shares of our common stock that were not exercisable and for which no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. Mr. Moore also agreed pursuant to the exchange agreement not to convert the promissory notes convertible into 800,000 shares of our common stock until the Company filed on amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to its authorized shares of common stock. In addition, the warrants to be issued in the exchange have an extended expiration date of two years following issuance.

In July 2012, we entered into exchange agreements with certain additional holders of an additional 23,726,545 warrants to purchase shares of our common stock. Similar to Mr. Moore, these holders have surrendered warrants to purchase an aggregate of approximately 23,726,545 shares of our common stock to us in exchange for receiving warrants to purchase the same aggregate amount of our common stock .These warrant shares were not exercisable and no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. In addition, warrants to be issued in the exchange have an extended expiration date of two years following issuance.

The Company recorded noncash income of approximately $408,000 as a result of these exchanges.

The Company has included the above exchanged warrants, aggregating to 34,791,156, in its total warrants of 100,322,588 as of October 31, 2012. These new warrants are expected to be issued by early 2013.

Expiration of Warrants

During the twelve months ended October 31, 2012, the Company had 15,869,507 warrants (“October 2007 warrants”), with anti-dilution provisions, and 400,000 warrants, with no such anti-dilution provisions, expire unexercised.

Warrants with anti-dilution provisions

Some of our warrants (approximately 13.1 million) contain anti-dilution provisions originally set at $0.20 with a term of five years. As of October 31, 2012 and 2011 these warrants had an exercise price of approximately $.15. If the Company issues any Common Stock , except for exempt issuances as defined in the Warrant for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “ weighted average” formula included in the Warrant. During October 2012, the Company issued shares to an investor from the partial conversion of a convertible promissory note at a conversion price of $0.0356. The anti-dilution provision requires the Company to issue approximately 42,400 additional warrant shares; and the exercise price to be lowered a de minimis amount ($0.1495). Any future financial offering or instrument issuance below the current exercise price will cause further anti-dilution and re-pricing provisions in approximately 13.1 million of our total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $0.1495 and $0.10, weighting the possibility of warrants being exercised at $0.1495 between 40% and 50% and warrants being exercised at $0.10 between 60% and 50%.

As of October 31, 2012, there were outstanding warrants to purchase 65,531,432 shares of our common stock and exchange warrants - nonexercisable to purchase 34,791,156 shares of our common stock with exercise prices ranging from $0.053 to $0.17 per share.

Embedded Derivative Liability

The Company has convertible features (Embedded Derivatives) in its outstanding convertible promissory notes. The Embedded Derivatives are recorded as liabilities at issuance. These Embedded Derivatives are valued using the Black-Scholes Model (BSM Model) and are subject to revaluation at each reporting date. Any change in fair value between reporting periods will be reported on the statement of operations.

At October 31, 2012, the fair value of the Embedded Derivative Liability was $0 as the related notes were paid off, converted or reached maturity. For the twelve months ended October 31, 2012 and October 31, 2011, the Company reported income of approximately $400,000 and approximately $1.9 million, respectively, due to changes in the fair value of the Embedded Derivative Liability partially resulting from debt to equity exchanges during the period.

The fair value of the Warrants and Embedded Derivatives are estimated using an adjusted BSM model. The Company computes multiple valuations, each quarter, using the BSM model for each derivative instrument to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the derivative at the reporting date. As of October 31, 2012, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $1.9 million and $0, respectively. As of October 31, 2011, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $6.4 million and $946,000, respectively. We increased income approximately $6.0 million for net changes in the fair value of the common stock warrant liability and embedded derivative liability for the year ended October 31, 2012. We increased income approximately $9.8 million for net changes in the fair value of the common stock warrant liability and embedded derivative liability for year ended October 31, 2011.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

STOCK OPTIONS :

12 Months Ended

Oct. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

11. STOCK OPTIONS:

The Company has one active stock and cash-based incentive plan, the 2011 Omnibus Incentive Plan (the “Plan”), pursuant to which the Company has granted stock options to executive officers, directors, employees and consultants. The Incentive Plan was adopted on August 22, 2011 and approved by the stockholders on September 27, 2011. An aggregate of 20,000,000 shares of our common stock (subject to adjustment by the compensation committee) are reserved and available for delivery under the 2011 Plan. On August 13, 2012, at our annual meeting, shareholders ratified and approved an amendment to our 2011 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan to 45,000,000. At October 31, 2012, the Company had granted 17,540,000 options to employees and consultants, at an exercise price, of approximately $0.15.

The 2011 Plan supersedes all of the Company’s previous stock option plans, which include the 2004 Stock Option Plan, the 2005 Stock Option Plan and the 2009 Stock Option plan under which the Company had options to purchase 2,381,525, 5,444,000 and 19,441,899 shares of common stock. The terms and conditions of the options outstanding under these plans remain unchanged. As of October 31, 2012, the Company had outstanding options of 44,807,424.

Total compensation cost for our stock plans recognized in the statement of operations for the year ended October 31, 2012 was approximately $1.09 million, of which approximately $480,000 was included in research and development expenses and approximately $610,000 was included in general and administrative expenses. For the year ended October 31, 2011, total compensation cost for our stock plans recognized in the statement of operations was approximately $651,000 of which approximately $272,000 was included in research and development expenses and approximately $379,000 was included in general and administrative expenses, respectively.

The fair value of options granted for the years ended October 31, 2012 and 2011 amounted to $2,539,792 and $103,125, respectively.

As of October 31, 2012, there was approximately $2,047,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 2.0 years.

A summary of the grants, cancellations and expirations (none were exercised) of the Company’s outstanding options for the periods starting with October 31, 2010 through October 31, 2012 is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2010		26,467,424			0.16		7.4		415,967
Granted		850,000			0.12		9.2		15,200
Cancelled or Expired		-			-		-		-
Outstanding as of October 31, 2011		27,317,424			0.16		8.1		367,417
Granted		17,540,000			0.15		9.0		-
Cancelled or Expired		(50,000	)		0.10		6.75		-
Outstanding as of October 31, 2012		44,807,424			0.16				-
Vested & Exercisable at October 31, 2012		29,278,169		$	0.16		5.75	$	-

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2012 and 2011 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s Common Stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options’ expected lives. The Company used their own historical volatility in determining the volatility to be used. Expected lives are based on contractual terms given the early stage of the business and lack of intrinsic value. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

	Year Ended			Year Ended
	October 31, 2012			October 31, 2011
Expected volatility		143.00	%		150.44	%
Expected Life		10.0 years			10.0 years
Dividend yield		0			0
Risk-free interest rate		2.10	%		3.50	%
Forfeiture Rate		4.4	%		4.4	%

2011 Employee Stock Purchase Plan

Our board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which we refer to as the ESPP, on August 22, 2011, and our stockholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 5,000,000 shares of our common stock are reserved for issuance under the ESPP.

During the twelve months ended October 31, 2012 approximately $18,300 was withheld from employees, on an after-tax basis, in order to purchase an aggregate of 207,077 shares of our common stock. There was no such activity during the twelve months ended October 31, 2011 as the ESPP was not available.

COMMITMENTS AND CONTINGENCIES :

12 Months Ended

Oct. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

12. COMMITMENTS AND CONTINGENCIES :

University of Pennsylvania

On May 10, 2010, we entered into a second amendment to the Penn license agreement pursuant to which we acquired exclusive licenses for an additional 27 patent applications related to our proprietary Listeria vaccine technology. As part of this amendment we exercised our option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in our common stock (approximately 388,889 shares of our common stock based on a price of $0.18 per share) and agreed to pay historical patent costs incurred by the University of Pennsylvania at a cost of approximately $462,000. As of October 31, 2012, the Company owed the University of Pennsylvania approximately $517,000 under all licensing agreements.

Numoda

On June 19, 2009 we entered into a Master Agreement and on July 8, 2009 we entered into a Project Agreement with Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda will be responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Per the agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 3,500,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through October 31, 2012, the Company has paid Numoda approximately $7.4 million.

Numoda -Stock Purchase Agreement

On June 13, 2012, we entered into a stock purchase agreement with Numoda Corporation pursuant to which we issued to Numoda 15 million shares of our common stock, which we refer to as the AR Cancellation Shares, at a purchase price per share of $0.15, in exchange for the immediate cancellation of $2,250,000 of accounts receivables owed by us to Numoda pursuant to the Master Agreement, dated June 19, 2009, between Numoda and us. In connection with such issuance, we registered the AR Cancellation Shares with the Securities and Exchange Commission. The Company recorded noncash income of approximately $869,000 as a result of this stock purchase agreement.

Numoda- Socius Stock Issuance

On July 24, 2012, the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which we refer to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which we refer to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which we refer to as the Claim. Socius purchased approximately $1.8 million of the Claim against us from Numoda Corporation.

Pursuant to the terms of the Order and the Stipulation, we issued and delivered to Socius an aggregate of 24,058,407 shares of our common stock for the entire Claim, which are subject to adjustment as described in the Stipulation. The Company recorded noncash income of approximately $618,000 related to the issuance of stock to Socius in settlement of the Claim.

As of October 31, 2012, the Company owed Numoda approximately $858,000, which is recorded in Accounts Payable at the balance sheet date.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10.000 square foot leased facility in Princeton, NJ. Costs approximate $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $38,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset, The remaining $16,000 went towards our first month of rent. The agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $337,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015.

Other

Pursuant to a Clinical Research Service Agreement, executed in April 2005, the Company is obligated to pay Pharm–Olam International for service fees related to our Phase I clinical trial. As of October 31, 2012, the Company has an outstanding balance of $223,620 on this agreement.

Moore Employment Agreement and Option Agreements. We are party to an employment agreement with Mr. Moore, dated as of August 21, 2007 (memorializing an oral agreement dated December 15, 2006), that provides that he will serve as our Chairman of the Board and Chief Executive Officer for an initial term of two years. For so long as Mr. Moore is employed by us, Mr. Moore is also entitled to nominate one additional person to serve on our board of directors. Following the initial term of employment, the agreement was renewed for a one year term, and is automatically renewable for additional successive one year terms, subject to our right and Mr. Moore’s right not to renew the agreement upon at least 90 days’ written notice prior to the expiration of any one year term.

Under the terms of the agreement, Mr. Moore was entitled to receive a base salary (currently $350,000 per year). This amount is subject to annual review for increases by our board of directors in its sole discretion. The agreement also provides that Mr. Moore is entitled to receive family health insurance at no cost to him. Mr. Moore’s employment agreement does not provide for the payment of a bonus.

We have also agreed to grant Mr. Moore 1,500,000 shares of our common stock if the price of common stock (adjusted for any splits) is equal to or greater than $0.40 for 40 consecutive business days. Pursuant to the terms of his employment agreement, all options will be awarded and vested upon a merger of the company which is a change of control or a sale of the company while Mr. Moore is employed. In addition, if Mr. Moore’s employment is terminated by us, Mr. Moore is entitled to receive severance payments equal to one year’s salary at the then current compensation level.

Mr. Moore has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 12 months thereafter under certain circumstances. In addition, Mr. Moore is subject to a non-solicitation provision for 12 months after termination of his employment.

Rothman Employment Agreement and Option Agreements. We previously entered into an employment agreement with Dr. Rothman, Ph.D., dated as of March 7, 2005, that provided that he would serve as our Vice President of Clinical Development for an initial term of one year. While the employment agreement has expired and has not been formally renewed in accordance with the agreement, Dr. Rothman remains employed by us and is currently our Executive V.P. of Clinical and Scientific Operations. Dr. Rothman’s current salary is $305,000, consisting of $275,000 in cash and $30,000, payable in our common stock.

Dr. Rothman has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 18 months thereafter under certain circumstances. In addition, Dr. Rothman is subject to a non-solicitation provision for 18 months after termination of his employment.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

INCOME TAXES:

12 Months Ended

Oct. 31, 2012

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

13. INCOME TAXES:

The income tax provision (benefit) consists of the following:

	October 31, 2012			October 31, 2011
Federal
Current	$	-		$	-
Deferred		(9,974,596	)		(1,292,094	)
State and Local
Current		(346,787	)		(379,472	)
Deferred		(1,826,038	)		(81,597	)
Change in valuation allowance		11,800,634			1,373,691
Income tax provision (benefit)	$	(346,787	)	$	(379,472	)

The Company has U.S. federal net operating loss carryovers (NOLs) of approximately $55,127,000 and $32,485,000 at October 31, 2012 and 2011, respectively, available to offset taxable income through 2032. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. The Company also has New Jersey State Net Operating Loss carry overs of $26,880,000 and $12,593,000, as of October 31, 2012 and October 31, 2011, respectively, available to offset future taxable income through 2032.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
Deferred Tax Assets	October 31, 2012			October 31, 2011

Net operating loss carryovers	$	21,162,237		$	12,994,244
Stock-based compensation		1,907,607			1,474,016
Other deferred tax assets		957,982			48,470
Total deferred tax assets	$	24,027,826		$	14,516,730
Valuation allowance		(22,414,639	)		(10,614,005	)
Deferred tax asset, net of valuation allowance	$	1,613,187		$	3,902,725

Deferred Tax Liabilities

Valuation of warrants		-			(3,241,085	)
Other deferred tax liabilities		(1,613,187	)		(661,640	)
Total deferred tax liabilities	$	(1,613,187	)	$	(3,902,725	)
Net deferred tax asset (liability)	$	-		$	-

The expected tax expense (benefit) based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Year ended October 31, 2012			Year ended October 31, 2011

US Federal statutory rate		(34.00	)%		(34.00	)%
State income tax, net of federal benefit		(5.9	)
Fair value of common stock warrant liability		(15.0	)
Deferred tax adjustment		(39.3	)
Change in valuation allowance		97.8			16.9
Other permanent differences		(6.5	)		12.6	%
Income tax provision (benefit)		(2.9	)%		(4.5	)%

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of our Net Operating Losses under the State of New Jersey NOL Transfer Program. In February 2011, the Company received a net cash amount of $379,742 from the sale of our state net operating losses (“NOLs”) through the year ending October 31, 2009. In January 2012, the Company received a net cash amount of $346,787 from the sale of our state NOLs for the periods through October 31, 2010. In December 2012, the Company received notification that it will receive a net cash amount of approximately $725,000 from the sale of our state NOLs and R&D tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2013.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on this assessment, management has established a full valuation allowance against all of the deferred tax assets for each period because it is more likely than not that all of the deferred tax assets will not be realized. The change in valuation allowance for the years ended October 31, 2012 and 2011 is $11,800,634 and $1,373,691, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

SHAREHOLDERS' EQUITY :

12 Months Ended

Oct. 31, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

14. SHAREHOLDERS’ EQUITY :

Equity Enhancement Program

On October 26, 2012, we entered into a Common Stock Purchase Agreement, with Hanover Holdings I, LLC, a New York limited liability company, , requires Hanover to purchase up to $10.0 million of shares of our common stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of common stock will be the higher of (i) the minimum price, ( Floor Price), set forth in our notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the common stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment.. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period.

In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, we have issued Hanover 3,500,000 Commitment Fee Shares. We have also agreed to issue Hanover additional Maintenance Fee Shares of our common stock in the event that no shares of common stock have been purchased or sold pursuant to the Agreement during any calendar quarter during the 24 month term. The number of Maintenance Fee Shares to be delivered to Hanover, from time to time, with respect to any calendar quarter, will be equal to approximately $15,000 worth of shares of common stock at a 10% discount to market.

The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that Hanover certain events related to a breach by us of any of our representations and warranties under the Hanover Purchase Agreement.

In connection with the Hanover Purchase Agreement, on October 26, 2012, we entered into a registration rights agreement with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, we agreed to prepare and file with the SEC one or more registration statements for the purpose of registering the resale of the common stock issued to Hanover. the Securities. We agreed to file the initial registration statement with the SEC within 12 calendar days of the Hanover Purchase Agreement and to use our commercially reasonable efforts to cause such registration statement to be declared effective within 90 calendar days of the Hanover Purchase Agreement (120 calendar days if the registration statement is reviewed by the SEC).

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances.

Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 40,500,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $0.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding. At various times through October 31, 2011, Optimus exercised 77,019,962 warrants, at prices ranging from $0.15 to $0.20, into shares of common stock and paid for such exercises with promissory notes totaling $13,049,210. In addition, the Company redeemed two hundred twenty-six (226) shares of Series B Preferred Stock held by the Investor for an aggregate redemption price of $3,141,004 consisting of (i) cash in an amount of $76,622 and (ii) cancellation of certain promissory notes issued by an affiliate of the Investor to the Company in the aggregate amount of $3,051,000 and accrued interest of approximately $13,382. This resulted in a net promissory note receivable of $9,998,210 as of October 31, 2011. The Company also recorded $485,812 and $285,300 in accrued interest on the promissory notes through October 31, 2012 and 2011, respectively. The value of the Promissory Note and Interest Receivable was $10,484,022 and $10,283,510 at October 31, 2012 and 2011, respectively. The promissory bears interest at 2 % per annum which is credited directly to capital.

On April 4, 2011,the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share (the “ Series B Preferred Stock ”) at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

In order to satisfy certain conditions set forth in the Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “ Additional Warrant ”) to purchase up to an additional 25,560,000 shares of the Company’s common stock, at an initial exercise price of $0.15 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “ Warrant Shares ”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Purchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “ Promissory Note ”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled.

Holders of Series B preferred stock will be entitled to receive dividends, which will accrue in shares of Series B preferred stock on an annual basis at a rate equal to 10% per annum from the issuance date. Accrued dividends will be payable upon redemption of the Series B preferred stock or upon the liquidation, dissolution or winding up of our company. In the event the company redeems all or a portion of any shares of the Series B Preferred Stock then held by Optimus, Optimus shall apply, and the Company may offset, the proceeds of any such redemption to pay down the accrued interest and outstanding principal of the Promissory Note from Optimus. At October 31, 2012 the Series B preferred stock had a liquidation preference of $9,722,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,322,570. During the years ended October 31, 2012 and 2011 and the period from March 1, 2002 (date of inception) to October 31, 2012, the Company accrued dividends of $740,000, $1,538,686 and $2,322,570 respectively.

On April 4, 2011, the Company and the Holder also entered into an Amended and Restated Security Agreement to ensure that any Promissory Note issued upon exercise of the Additional Warrant will be entitled to the benefits of the security and collateral provisions of the Security Agreement dated as of July 19, 2010.

During the year ended October 31, 2011 the Company issued and sold 177 shares of non-convertible, redeemable Series B Preferred Stock to Optimus pursuant to the terms of a Preferred Stock Purchase. Prior to closing on the Preferred Stock purchase, the Company received $300,000 from Optimus in exchange for promissory notes (subsequently repaid at closing). The Company received gross proceeds of $1.47 million (net proceeds of $1.34 million) from this transaction.

In connection with these transactions, Optimus exercised 15,752,903 warrants at exercise prices ranging from $.15 to $.155. In addition, on April 4, 2011, under an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010, the Company issued Optimus a three-year warrant to purchase 25,560,000 shares of the Company’s common stock at an initial exercise price of $0.15. As of both October 31, 2011 and 2012 these 25,560,000 warrants remained outstanding. During December 2011, the Company unreserved for issuance shares related to the 25,560,000 preferred stock warrants.

As of both October 31, 2011 and 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

12 Months Ended

Oct. 31, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

15. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

· Level 1 — Quoted prices in active markets for identical assets or liabilities

· Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

· Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of October 31, 2012:

October 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.053 - $0.17 from October 2012 through August 2017	$	-	$	$	434,136	$	434,136
Embedded Derivative Liability							-

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664
Other Short-term Notes Payable – not measured at fair value (net of debt discount of $4,541 related to unamortized OID)							371,968
Short-term convertible Notes and FV of Embedded Derivative						$	2,015,509

October 31, 2011	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.15 - $0.1952 from February 2011 through November 2015	$	-	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012				$	946,046	$	946,046

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the twelve months ended October 31, 2012 and October 31, 2011.

Common stock warrant liability:

	October 31, 2012			October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071		$	13,006,194
Issuance of common stock warrants		-			600,407
Exercises and Exchanges of warrants		59,572			(1,295,884	)
Change in fair value		(923,052	)		(3,789,889	)
Balance at January 31, 2012 and 2011	$	5,527,591		$	8,520,828

Issuance of common stock warrants		-			3,111,758
Exercises of warrants		-			(639,960	)
Exchanges of warrants		(134,796	)		-
Change in fair value		(2,302,707	)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088		$	15,908,302
Issuance of common stock warrants		291,400			41,344
Reclassification of liabilities to equity		-
Debt for Equity Exchange: Bridge Notes		(4,750	)		-
July Warrant Exchanges		(407,501	)		-
Exercises and/or Exchanges of warrants		-			(1,186,959	)
Change in fair value		(1,703,252	)		(6,826,019	)
Balance at July 31, 2012 and 2011		1,265,985			7,936,668
Issuance of common stock warrants		36,134			-
Reclassification of warrant liability to equity		-			(186,908	)
Exchange of warrants		-			816,259
Issuance of additional warrants due to anti-dilution provisions		150			-
Change in fair value		(868,133	)		(2,174,948	)
Balance at October 31, 2012 and 2011		434,136			6,391,071

Embedded Derivative Liability

	October 31, 2012			October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046		$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568			3,505,605
Note Conversions and Payoffs		(836,468	)		(683,977	)
Debt for Equity Exchange		(115,046	)		(190,449
Change in fair value		(301,100	)		(1,766,161
Ending balance	$	-		$	946,046

May 2012 Notes	October 31, 2012

Issuance of notes		687,000

Issuance of C/S warrants		(291,400	)

Changes in fair value		192,713

	$	588,313

Hanover PIPE Notes	October 31, 2012

Issuance of notes		265,000


Changes in fair value		97,791

	$	362,791

Magna Exchange Note	October 31, 2012

Issuance of notes		400,075

Conversions to common stock		(100,000	)
Changes in fair value		33,011

	$	333,086

Asher Note
Issuance of notes		103,500

Changes in fair value		47,187

	$	150,687

French, Patton & Paterson Notes

Issuance of notes		175,000
Issuance of warrants		(36,134	)
Changes in fair value		69,798

	$	208,664

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUBSEQUENT EVENTS

12 Months Ended

Oct. 31, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

16. SUBSEQUENT EVENTS

Asher Note

On November 12, 2012, in a private placement pursuant to a note purchase agreement, we issued Asher Enterprises, Inc, which we refer to as Asher, a convertible promissory note in the aggregate principal amount of $153,500 for a purchase price of $150,000, which we refer to as the November Asher Note. The November Asher Note bears interest at a rate of 8% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of the November Asher Note. The November Asher Note is convertible into shares of our common stock at a conversion price equal to 65% of the arithmetic average of the four lowest closing trading prices for the common stock during the 20 trading day period ending on the latest complete trading day prior to the applicable conversion date. The November Asher Note matures on August 14, 2013, nine months from its issuance date. The November Asher Note may be converted by Asher, at its option, in whole or in part. The September Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the September Asher Note to the extent that after such conversion Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

Private Placements of Convertible Notes to Hanover

On December 6, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which we refer to as the Hanover December 2012 Note. The Hanover December 2012 Note bears interest at a rate of 12% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover December 2012 Note. The Hanover December 2012 Note is convertible into shares of our common stock at a conversion price of $0.03 per share. On December 5, Hanover exchanged the Initial Hanover PIPE Notes for convertible notes in the form of the Hanover December 2012 Note in all material respects (other than date of issuance, exchange date, the maturity date of May 19, 2012 solely with respect to the Exchanged Hanover PIPE Note issued in exchange for the Hanover September 2012 PIPE Note and the maturity date of June 19, 2013 solely with respect to the Exchanged Hanover PIPE Note issued in exchange for the Hanover October 2012 PIPE Note) that also are convertible into shares of our common stock at a conversion price of $0.03 per share, which we refer to as the Exchanged Hanover PIPE Notes. Each of the Hanover December 2012 Note and the Exchanged Hanover PIPE Notes are subject to limitations on conversion if after giving effect to such conversion Hanover would beneficially own more than 4.99% of our common stock.

Other Hanover Related Transactions

During November and December, 2012, pursuant to the terms of various Assignment Agreements, we delivered convertible notes to Magna in an aggregate principal amount of $340,522, convertible into shares of common stock, which we refer to as the Magna Exchange Notes. The Magna Exchange Notes bear interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Second Magna Exchange Note. Prior to the date of this filing, all Magna Exchange Notes (including the $400K Magna note in Footnote 6) have been converted in full into 25,315,171 shares of our common stock in accordance with its terms and no longer remains outstanding.

Ironridge Settlement

On December 20, 2012, the Superior Court of the State of California for the County of Los Angeles – Central District entered an Order for Approval of Stipulation for Settlement of Claims, which we refer to as the Order, in the matter titled Ironridge Global IV, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement of Claims, which we refer to as the Stipulation, dated December 19, 2012, between us and Ironridge Global IV, Ltd., which we refer to as Ironridge, provides for the full and final settlement of Ironridge’s $692,761 claim against us in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which we refer to as the Claim. Pursuant to the terms of the Order and the Stipulation, we are obligated to issue 33,389,663 shares of our common stock to settle the $692,761 owed. On December 21, 2012, we issued and delivered to Ironridge 45,000,000 shares of our common stock, par value $0.001 per share. Accordingly, Ironridge will return 11,610,337 shares of our common stock.

JMJ Note

On December 26, 2012, in a private placement pursuant to a note purchase agreement, we issued JMJ Financial a convertible promissory note for a purchase price of $100,000, which we refer to as the December 2012 Note. If the December 2012 Note is repaid on or before January 31, 2013, we will pay JMJ Financial a principal amount of $125,000. If the December 2012 Note is rolled into a future financing, we will have to pay JMJ Financial a principal amount of $115,000. At the holder’s election, principal and interest can be converted at a conversion price equal to 70% of the lowest closing trading price for our common stock during the 25 trading day period ending on the latest complete trading day prior to the applicable conversion date.

Sale of stock under the Equity Enhancement Program

Under the Hanover Purchase Agreement, the Company may require Hanover Holdings to purchase up to $10.0 million of our common stock over a 24 month period (See Footnote 13 – Shareholders’ Equity).

On December 31, 2012, we issued 6,990,514 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $0.0266 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We received total net proceeds of $185,975 in connection with this draw down.

On January 17, 2013, we issued 4,400,000 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $0.0374 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We received total net proceeds of $164,656.80 in connection with this draw down.

On February 12, 2013, we issued 8,000,000 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $0.0644 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We receive total net proceeds of $515,520 in connection with this draw down.

Tonaquint Note

On December 13, 2012, we entered into an agreement, which we refer to as the Tonaquint Purchase Agreement, with Tonaquint, Inc., which we refer to as Tonaquint, whereby we issued Tonaquint a secured convertible promissory note for the initial principal sum of $890,000, which we refer to as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can be converted at a fixed price of $0.16 per share but is subject to reduction in the event that we issue shares below the conversion price of $0.16.

On the closing date, Tonaquint (i) funded us with $490,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 2. Mortgage Note 1 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 8 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.

We have agreed to make installment payments on the Tonaquint Note beginning 6 months after closing in cash or in stock. If we choose to make installment payments in stock, then such stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date. Tonaquint has the right to receive additional shares if the market price of our common stock is lower than the price per share of our common stock on the installment date.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Polices)

12 Months Ended

Oct. 31, 2012

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Capitalization of Deferred Policy Acquisition Costs, Policy [Policy Text Block]

Deferred financing costs

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

	As of October 31,
	2012		2011
Warrants		100,322,588		137,841,857
Stock Options		44,807,424		27,317,424
Convertible Debt (using the if-converted method)		33,919,264		61,660,382
Total		179,049,276		226,819,663

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Based Compensation

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of financial instruments

Derivatives, Embedded Derivatives [Policy Text Block]

Derivative Financial instruments

Debt Discount and Amortization Of Debt Discount [Policy Text Block]

Debt discount and amortization of debt discount

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Income Tax, Policy [Policy Text Block]

Income Taxes

Reclassification, Policy [Policy Text Block]

Reclassification

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Oct. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. For 2012 and 2011, approximately 55 million warrants and 49.4 million warrants, respectively (excluding approximately $25.6 million warrants, held by an affiliate of Optimus) include anti-dilutive provisions to adjust the number and price of the warrants based on certain types of equity transactions.

	As of October 31,
	2012		2011
Warrants		100,322,588		137,841,857
Stock Options		44,807,424		27,317,424
Convertible Debt (using the if-converted method)		33,919,264		61,660,382
Total		179,049,276		226,819,663

SHARE-BASED COMPENSATION EXPENSE (Tables)

12 Months Ended

Oct. 31, 2012

Share-Based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The effect on the Company’s net loss would have been as follows for the period March 1, 2002 (date of inception) to October 31, 2012:

	March 1, 2002 (date of inception) to October 31, 2012
Net Loss as reported	$	(47,557,543	)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176	)
Adjusted Net Loss	$	(47,796,502	)

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Oct. 31, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consists of the following:

	October 31, 2012			October 31, 2011
Laboratory Equipment	$	287,518		$	195,672
Accumulated Depreciation		(209,450	)		(195,672	)
Net Property and Equipment	$	78,068		$	-

INTANGIBLE ASSETS (Tables)

12 Months Ended

Oct. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	October 31, 2012			October 31, 2011
License	$	651,992		$	651,992
Patents		2,422,409			2,117,505
Total intangibles		3,074,401			2,769,497
Accumulated Amortization		(660,646	)		(512,645	)
Intangible Assets	$	2,413,755		$	2,256,852

Schedule of Expected Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013			140,000
2014			140,000
2015			140,000
2016			140,000
2017			140,000

ACCRUED EXPENSES: (Tables)

12 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

The following table represents the major components of accrued expenses:

	October 31, 2012		October 31, 2011
Salaries and other compensation	$	774,001	$	531,040
Clinical Trial		56,468		2,358,248
Vendors		77,512		-
Consultants		32,200		32,200
Financing costs		174,970		-
Legal		214,902		46,346
Interest Payable		28,859		-
Other		8,500		8,500
	$	1,367,412	$	2,976,334

CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE (Tables)

12 Months Ended

Oct. 31, 2012

Convertible Notes Payable [Abstract]

Schedule of Debt [Table Text Block]

Convertible Notes payable consist of the following:

	October 31, 2012		October 31, 2011
May 2011 Note Financing	$	—	$	3,392,158
October 2011 Note Financing		58,824		1,341,738
December 2011 Note Financing		131,928		—
May 2012 Note Financing		588,313		—
Bridge Notes		185,758		711,701
JMJ Financial		73,590		570,802
Hanover Holdings Note		362,791		—
Magna		333,086		—
Chris French		25,950		—
Asher		150,687		—
Yvonne Paterson		103,804		—
James Patton		78,909		—

Total Convertible Notes		2,093,640		6,016,399

Unamortized discount	(4,541	)	(1,300,345	)

Derivative Liability	—		946,046

	2,089,099		5,662,100

Current Portion of Convertible Notes		2,089,099		5,091,298

Long-term Convertible Notes less current portion	$	—	$	570,802

DERIVATIVES (Tables)

12 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments [Table Text Block]

The table below lists the Company’s derivative instruments as of October 31, 2012 and 2011:

Description	Principal			Original Issue Discount			Warrant Liability			Embedded Derivative Liability
Total Valuation at October 31, 2010	$	777,154		$	21,937		$	13,006,194		$	81,028
Issuance of November 2010 Bridge Notes		931,579			96,579			391,076			150,156
Exchange of November 2010 Bridge Notes		17,175			17,175			86,963			9,389
Issuance of January 2011 Bridge Notes		452,941			57,941			173,808			41,024
Note Payoffs		(187,582	)
Issuance of Warrants								35,523
Accreted Interest					(73,363	)
Exercise of Warrants								(1,382,847	)
Change in FV								(3,789,889	)		(51,972	)
Total Valuation at January 31, 2011		1,991,267			120,269			8,520,828			229,625

Issuance of Q2 2011 Bridge Notes		473,392			43,392			121,238			71,336
Issuance of Long-term Convertible Promissory Notes		626,400									-
Note Payoffs		(159,675	)								(5,904	)
Issuance of Warrants								2,990,520
Accreted Interest					(74,422	)
Exercise of Warrants								(639,960	)
Change in FV								4,915,676			763,523
Total Valuation at April 30, 2011	$	2,931,384		$	89,239		$	15,908,302		$	1,058,580

Issuance of Q3 2011 Bridge Notes		11,765			1,765			4,968			5,051
Issuance of May 2011 Notes		7,077,936			1,553,254			-			2,719,345
Note Payoffs		(26,316	)								(8,860	)
Additional warrants issued to Bridge Note holder								36,376
Exchange of Bridge Notes		8,033			8,033						2,656
Conversion of Bridge Notes		(1,164,947	)								(381,209	)
Conversion of May 2011 Notes		(671,500	)								(166,980	)
Exchanges/Exercises of October 2007 Warrants								(1,186,959	)
Accreted Interest					(340,050	)
Change in FV								(6,826,019	)		(2,141,984	)
Total Valuation at July 31, 2011	$	8,166,355			1,312,241			7,936,668			1,086,599
Issuance of October 2011 Notes		2,326,471			459,396			-			396,818
Note Payoffs		(155,806	)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788	)								(10,530	)
Conversion of May 2011 Notes		(1,225,561	)								(110,494	)
Reclassification of Warrant liability to Equity								(186,908	)
Exchange of Warrants								816,259
Accreted Interest					(471,290	)
Change in FV								(2,174,948	)		(416,347	)
Total Valuation at October 31, 2011	$	8,976,071			1,300,347			6,391,071			946,046
Issuance of December 2011 Notes		1,232,353			258,178			-			306,568
Conversion of Bridge Notes		(169,000	)								-
Conversion of May 2011 Notes		(1,924,060	)								(341,342	)
Conversion of October 2011 Notes		(1,227,500	)								(329,433	)
Partial Note Repayments		(52,941	)
Conversion of Long-term Convertible Promissory Notes		(540,000	)
Exchange of Warrants								59,572
Accreted Interest					(532,559	)
Change in FV								(923,052	)		159,657
Total Valuation at January 31, 2012	$	6,294,923		$	1,025,966		$	5,527,591		$	741,496
Exchange of Bridge Notes		52,941						-
Conversion of May 2011 Notes		(38,000	)								(5,016	)
Conversion of December 2011 Notes		(827,500	)								(160,677	)
Exchange of Warrants								(134,796	)
Accreted Interest					(569,419	)
Change in FV								(2,302,707	)		(438,054	)
Total Valuation at April 30, 2012	$	5,482,364		$	456,547		$	3,090,088		$	137,749
Issuance of May 2012 Notes		953,333						291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673	)		(200,632	)					(115,046	)
Debt for Equity Exchange: Bridge Notes		(50,000	)					(4,750	)
July 2012Exchange of Warrants								(407,501	)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800	)
Accreted Interest					(229,392	)
Change in FV								(1,703,252	)		(20,567	)
Total Valuation at July 31, 2012	$	1,739,224			26,523			1,265,985			2,136
Issuance of Patton Note		66,667						13,311
Issuance of French Note		25,000						4,565
Issuance of Paterson Note		100,000						18,258
Issuance of Hanover September Note		132,500
Issuance of Asher Note		103,500
Issuance of Hanover October Note		132,500
Issuance of JMJ Note		100,000
Assignment of Notes to Magna		(384,264	)
New Magna Note (result of above assignment)		400,075
Magna Conversions		(100,000	)
Accreted Interest					(21,984	)
Additional warrants issued due to investors due to anti-dilution provision								150
Change in FV								(868,133	)		(2,136	)
Total Valuation at October 31, 2012	$	2,315,202			4,541			434,136			-

Schedule Of Derivative Instruments Warrants [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable	$	0.15		34,791,156	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	0.15		3,578,949	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		1,453,553	October 2014-October 2015	October 2011 Convertible Debt Financing

Common Stock Purchase Warrant	$	0.15		2,213,234	January 2015-January 2016	December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		2,777,777	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.1495-0.17		24,754,595	January 2013-April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		46,956	N/A	Vendor & Other
Common Stock Purchase Warrant	$	0.15		3,735,430	May 2014 – May 2017	Placement Agent – Convertible Debt Financing
Common Stock Purchase Warrant	0.0530-0.15			1,410,938	October 2015-August 2017	August – September 2012 Convertible Promissory Notes

		Subtotal:		74,762,588
Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Preferred Stock Agreement (4/04/2011)
	Grand Total			100,322,588

(1)

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant	$	0.15		47,090,487	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant	$	0.15		287,001	August 2012	August 2007 Notes
Common Stock Purchase Warrant	$	0.15		23,593,122	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15		7,754,902	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	0.15 - $0.17		22,630,101	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant	$	0.15		7,674,512	August 2014	Executive Officer
Common Stock Purchase Warrant	$	0.15-$0.1952		446,956	February 2012	Vendor & Other
Common Stock Purchase Warrant	$	0.15		2,804,776	May 2014 - November 2015	Placement Agent – Convertible Debt Financing
	Subtotal			112,281,857

Common Stock Purchase Warrant	TBD (1)			25,560,000	April 2014	Optimus Preferred Stock Agreement (4/04/2011)
	Grand Total			137,841,857

(1)

Schedule Of Share Based Compensation Of Fair Value Of Options Using Black Scholes Option Pricing Model [Table Text Block]

The fair value of the warrant liability, as of October 31, 2011, was approximately $6.39 million. In fair valuing the warrant liability, at October 31, 2012 and October 31, 2011, the Company used the following inputs in its BSM Model:

	10/31/2012		10/31/2011

Exercise Price:		0.053-0.17		0.15-0.17

Stock Price		0.045		0.141

Expected term:		81-1736 days		289-1219 days

Volatility %		66.51%-146.78%		60.23%-163.40%

Risk Free Rate:		.09%-.72%		.09-.56%

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41678-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

+ Details

STOCK OPTIONS : (Tables)

12 Months Ended

Oct. 31, 2012

Equity [Abstract]

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value

Outstanding as of October 31, 2010		26,467,424			0.16		7.4		415,967
Granted		850,000			0.12		9.2		15,200
Cancelled or Expired		-			-		-		-
Outstanding as of October 31, 2011		27,317,424			0.16		8.1		367,417
Granted		17,540,000			0.15		9.0		-
Cancelled or Expired		(50,000	)		0.10		6.75		-
Outstanding as of October 31, 2012		44,807,424			0.16				-
Vested & Exercisable at October 31, 2012		29,278,169		$	0.16		5.75	$	-

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

	Year Ended			Year Ended
	October 31, 2012			October 31, 2011
Expected volatility		143.00	%		150.44	%
Expected Life		10.0 years			10.0 years
Dividend yield		0			0
Risk-free interest rate		2.10	%		3.50	%
Forfeiture Rate		4.4	%		4.4	%

INCOME TAXES : (Tables)

12 Months Ended

Oct. 31, 2012

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The income tax provision (benefit) consists of the following:

	October 31, 2012			October 31, 2011
Federal
Current	$	-		$	-
Deferred		(9,974,596	)		(1,292,094	)
State and Local
Current		(346,787	)		(379,472	)
Deferred		(1,826,038	)		(81,597	)
Change in valuation allowance		11,800,634			1,373,691
Income tax provision (benefit)	$	(346,787	)	$	(379,472	)

Summary of Operating Loss Carryforwards [Table Text Block]

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
Deferred Tax Assets	October 31, 2012			October 31, 2011

Net operating loss carryovers	$	21,162,237		$	12,994,244
Stock-based compensation		1,907,607			1,474,016
Other deferred tax assets		957,982			48,470
Total deferred tax assets	$	24,027,826		$	14,516,730
Valuation allowance		(22,414,639	)		(10,614,005	)
Deferred tax asset, net of valuation allowance	$	1,613,187		$	3,902,725

Deferred Tax Liabilities

Valuation of warrants		-			(3,241,085	)
Other deferred tax liabilities		(1,613,187	)		(661,640	)
Total deferred tax liabilities	$	(1,613,187	)	$	(3,902,725	)
Net deferred tax asset (liability)	$	-		$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The expected tax expense (benefit) based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Year ended October 31, 2012			Year ended October 31, 2011

US Federal statutory rate		(34.00	)%		(34.00	)%
State income tax, net of federal benefit		(5.9	)
Fair value of common stock warrant liability		(15.0	)
Deferred tax adjustment		(39.3	)
Change in valuation allowance		97.8			16.9
Other permanent differences		(6.5	)		12.6	%
Income tax provision (benefit)		(2.9	)%		(4.5	)%

FAIR VALUE (Tables)

12 Months Ended

Oct. 31, 2012

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of October 31, 2012:

October 31, 2012	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.053 - $0.17 from October 2012 through August 2017	$	-	$	$	434,136	$	434,136
Embedded Derivative Liability							-

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	-	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664
Other Short-term Notes Payable – not measured at fair value (net of debt discount of $4,541 related to unamortized OID)							371,968
Short-term convertible Notes and FV of Embedded Derivative						$	2,015,509

October 31, 2011	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $0.15 - $0.1952 from February 2011 through November 2015	$	-	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012				$	946,046	$	946,046

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

May 2012 Notes	October 31, 2012

Issuance of notes		687,000

Issuance of C/S warrants		(291,400	)

Changes in fair value		192,713

	$	588,313

Hanover PIPE Notes	October 31, 2012

Issuance of notes		265,000


Changes in fair value		97,791

	$	362,791

Magna Exchange Note	October 31, 2012

Issuance of notes		400,075

Conversions to common stock		(100,000	)
Changes in fair value		33,011

	$	333,086

Asher Note
Issuance of notes		103,500

Changes in fair value		47,187

	$	150,687

French, Patton & Paterson Notes

Issuance of notes		175,000
Issuance of warrants		(36,134	)
Changes in fair value		69,798

	$	208,664

Embedded Derivative Liability [Member]

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Embedded Derivative Liability

	October 31, 2012			October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046		$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568			3,505,605
Note Conversions and Payoffs		(836,468	)		(683,977	)
Debt for Equity Exchange		(115,046	)		(190,449
Change in fair value		(301,100	)		(1,766,161
Ending balance	$	-		$	946,046

Common Stock Warrant Liability [Member]

Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the twelve months ended October 31, 2012 and October 31, 2011.

Common stock warrant liability:

	October 31, 2012			October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071		$	13,006,194
Issuance of common stock warrants		-			600,407
Exercises and Exchanges of warrants		59,572			(1,295,884	)
Change in fair value		(923,052	)		(3,789,889	)
Balance at January 31, 2012 and 2011	$	5,527,591		$	8,520,828

Issuance of common stock warrants		-			3,111,758
Exercises of warrants		-			(639,960	)
Exchanges of warrants		(134,796	)		-
Change in fair value		(2,302,707	)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088		$	15,908,302
Issuance of common stock warrants		291,400			41,344
Reclassification of liabilities to equity		-
Debt for Equity Exchange: Bridge Notes		(4,750	)		-
July Warrant Exchanges		(407,501	)		-
Exercises and/or Exchanges of warrants		-			(1,186,959	)
Change in fair value		(1,703,252	)		(6,826,019	)
Balance at July 31, 2012 and 2011		1,265,985			7,936,668
Issuance of common stock warrants		36,134			-
Reclassification of warrant liability to equity		-			(186,908	)
Exchange of warrants		-			816,259
Issuance of additional warrants due to anti-dilution provisions		150			-
Change in fair value		(868,133	)		(2,174,948	)
Balance at October 31, 2012 and 2011		434,136			6,391,071

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Textual)	12 Months Ended
	Oct. 31, 2012 USD ($)
Aggregate Additional Capital Raised From Sale Of Debt and Equity Securities	$ 950,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	12 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Total	179,049,276	226,819,663
Warrant [Member]
Total	100,322,588	137,841,857
Stock Options [Member]
Total	44,807,424	27,317,424
Convertible Debt Securities [Member]
Total	33,919,264	61,660,382

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	12 Months Ended
	Oct. 31, 2012	Oct. 31, 2011
Accumulated Amortization of Other Deferred Costs	$ 89,976	$ 11,152
Total	179,049,276	226,819,663
Property, Plant and Equipment, Estimated Useful Lives	3 to 5 years
Warrant [Member]
Total	55,000,000	49,400,000
Optimus Warrant [Member]
Total	25,600,000

- Definition

+ References

+ Details

SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	10 Months Ended	12 Months Ended							128 Months Ended
SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2009	Oct. 31, 2008	Oct. 31, 2007	Oct. 31, 2006	Dec. 31, 2003	Oct. 31, 2012
Net Loss as reported	$ 166,936	$ 12,069,687	$ 8,115,740	$ (929,244)	$ 5,416,418	$ 2,454,453	$ 6,197,744	$ 909,745	$ 47,557,543
Add: Stock based option expense included in recorded net loss									89,217
Deduct stock option compensation expense determined under fair value based method									(328,176)
Adjusted Net Loss									$ (47,796,502)

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Laboratory Equipment	$ 287,518	$ 195,672
Accumulated Depreciation	(209,450)	(195,672)
Net Property and Equipment	$ 78,068	$ 0

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

PROPERTY AND EQUIPMENT (Details Textuals) - USD ($)	12 Months Ended		128 Months Ended
PROPERTY AND EQUIPMENT (Details Textuals) - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Depreciation expense	$ 13,776	$ 28,406	$ 209,448

INTANGIBLE ASSETS (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
License	$ 651,992	$ 651,992
Patents	2,422,409	2,117,505
Total intangibles	3,074,401	2,769,497
Accumulated Amortization	(660,646)	(512,645)
Intangible Assets	$ 2,413,755	$ 2,256,852

INTANGIBLE ASSETS (Details 1)	Oct. 31, 2012 USD ($)
2013	$ 140,000
2014	140,000
2015	140,000
2016	140,000
2017	$ 140,000

INTANGIBLE ASSETS (Details Textual) - USD ($)	12 Months Ended		128 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012
Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs	$ 33,000		$ 33,000
Amortization expense of intangibles	$ 148,002	$ 132,288	$ 742,642
Minimum [Member]
Finite Lived Patents Expirations	2014
Maximum [Member]
Finite Lived Patents Expirations	2023

ACCRUED EXPENSES: (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Salaries and other compensation	$ 774,001	$ 531,040
Clinical Trial	56,468	2,358,248
Vendors	77,512	0
Consultants	32,200	32,200
Financing costs	174,970	0
Legal	214,902	46,346
Interest Payable	28,859	0
Other	8,500	8,500
Accrued Liabilities, Current	$ 1,367,412	$ 2,976,334

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE (Details) - USD ($)	Oct. 31, 2012	May 14, 2012	Dec. 29, 2011	Oct. 31, 2011	May 09, 2011
Total Convertible Notes	$ 2,093,640			$ 6,016,399
Unamortized discount	4,541			1,300,345
Derivative Liability	0			946,046
Long-term Debt	2,089,099			5,662,100
Current Portion of Convertible Notes	2,089,099			5,091,298
Long-term Convertible Notes less current portion	0			570,802
May 2011 Note Financing [Member]
Total Convertible Notes	0			3,392,158	$ 7,100,000
October 2011 Note Financing [Member]
Total Convertible Notes	58,824			1,341,738
Unamortized discount	(984,733)			(2,705)
December 2011 Note Financing [Member]
Total Convertible Notes	131,928		$ 1,232,000	0
May 2012 Note Financing [Member]
Total Convertible Notes	588,313	$ 953,333		0
Bridge Notes [Member]
Total Convertible Notes	185,758			711,701
Jmj Financial [Member]
Total Convertible Notes	73,590			570,802
Hanover Holdings Note [Member]
Total Convertible Notes	362,791			0
Magna [Member]
Total Convertible Notes	333,086			0
Chris French [Member]
Total Convertible Notes	25,950			0
Asher [Member]
Total Convertible Notes	150,687			0
Yvonne Paterson [Member]
Total Convertible Notes	103,804			0
James Patton [Member]
Total Convertible Notes	$ 78,909			$ 0

CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE (Details Textual)			1 Months Ended							2 Months Ended	3 Months Ended		12 Months Ended							128 Months Ended
	May 14, 2012 USD ($) $ / shares	May 09, 2011 USD ($) $ / shares	Aug. 27, 2012 USD ($) $ / shares	Jul. 31, 2012 USD ($) shares	Jul. 21, 2012 USD ($)	Dec. 29, 2011 USD ($) $ / shares	Nov. 30, 2011 USD ($) shares	Oct. 28, 2011 USD ($) $ / shares	Aug. 19, 2011 shares	Dec. 31, 2011 USD ($) $ / shares	Oct. 31, 2012 USD ($) $ / shares shares	Apr. 30, 2011 USD ($) shares	Oct. 31, 2012 USD ($) $ / shares shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares	Oct. 31, 2007 USD ($) shares	Oct. 31, 2006 USD ($)	Oct. 31, 2005 USD ($) shares	Dec. 31, 2003 USD ($)	Oct. 31, 2012 USD ($) $ / shares shares	Dec. 06, 2012 USD ($) $ / shares	Oct. 19, 2012 USD ($)	Sep. 27, 2012 USD ($)	Sep. 25, 2012 USD ($)	Sep. 19, 2012 USD ($)	Sep. 11, 2012 USD ($)	Aug. 02, 2012 USD ($)	Jan. 31, 2012 $ / shares	Jul. 31, 2011 USD ($)	Jul. 31, 2011 ALL (L)	May 31, 2011 USD ($)	Apr. 28, 2011 USD ($) $ / shares	Dec. 17, 2003 USD ($)
Convertible Notes Payable											$ 2,093,640		$ 2,093,640	$ 6,016,399						$ 2,093,640
Debt Instrument Purchase Price	$ 715,000					$ 1,000,000															$ 100,000											$ 2,300,000
Debt Instrument, Convertible, Conversion Price \| $ / shares	$ 0.15	$ 0.15	$ 0.15			$ 0.15				$ 0.15	$ 0.15		$ 0.15		$ 0.15					$ 0.15	$ 0.03							$ 0.15				$ 0.15
Debt Instrument, Maturity Date		May 12, 2012			Dec. 31, 2012	Jan. 09, 2015		Oct. 31, 2014
Debt Conversion, Converted Instrument, Amount			$ 100,000	$ 4,017,000			$ 660,000			$ 169,000			$ 4,500,000			$ 1,000,010	$ 300,000	$ 613,518	$ 15,969
Debt Conversion, Converted Instrument, Shares Issued \| shares				26,780,392			3,600,000					4,000,000	52,200,000			6,974,202		2,136,441
Other Noncash Expense												$ 805,000	$ 5,000
Issuance of notes					$ 250,000						$ 400,075		400,075							$ 400,075
Long-term Debt, Gross	$ 953,333				$ 250,000					$ 50,000	400,075		400,075	50,000						400,075		$ 132,500	$ 25,000	$ 100,000	$ 132,500	$ 103,500	$ 66,667				$ 59,000		$ 40,000
Original Issue Discount, net of accreted interest											(4,541)		(4,541)	(1,300,345)						(4,541)
Repayments of Debt								$ 400,000
(Loss) on note retirement													$ (2,187,787)	(461,595)	$ 41,000					(992,942)
Fair Value Of Warrants Issued \| shares													80,000
Long-term Debt											2,089,099		$ 2,089,099	5,662,100						2,089,099
Exchange Agreement Amount											300,000		300,000							300,000
Exchange Agreement Amount Debt Issued Value											$ 352,941		$ 352,941							$ 352,941
Exchange Agreement Shares Issuable Upon Excercise Of Warrants \| shares											2,352,940		2,352,940							2,352,940
Exchange Agreement Warrants Excercise Price \| $ / shares											$ 0.15		$ 0.15							$ 0.15
Loss On Note Retirement											$ 247,000		$ 247,000							$ 247,000
Debt Instrument, Maturity Date Range, Start													Dec. 31, 2010
Debt Instrument, Maturity Date Range, End													Apr. 30, 2011
Notes Payable														13,049,210
Debt Instrument, Interest Rate, Stated Percentage					33.00%																											8.00%
Third Investor [Member]
(Loss) on note retirement													$ 22,000
Fair Value Of Warrants Issued \| shares													27,000
Bridge Loan [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares											$ 0.15		$ 0.15							$ 0.15
Debt Conversion, Converted Instrument, Amount													$ 169,000
Debt Conversion, Converted Instrument, Shares Issued \| shares											0.15		1,126,667
Minimum Percentage Of Warrant Received Coverage				23.00%
Maximum Percentage Of Warrant Received Coverage				75.00%
Repayments of Debt													$ 53,000
(Loss) on note retirement													27,000
May 2011 Note Financing [Member]
Convertible Notes Payable		$ 7,100,000									$ 0		$ 0	$ 3,392,158						$ 0
Debt Instrument Purchase Price		$ 6,000,000
Debt Instrument Discount Percentage		15.00%
Debt Instrument, Payment Terms		Each investor paid $0.85 for each $1.00 of principal amount of May 2011 Notes purchased at the closing on May 12, 2011.
Debt Instrument, Convertible, Conversion Price \| $ / shares		$ 0.15									$ 0.15		$ 0.15	$ 0.15						$ 0.15
Percentage Of Common Stock Issuable Upon Conversion		50.00%
Debt Instrument, Maturity Date		May 12, 2012
Change In Fair Value Of Embedded Conversion Option and Warrants		$ 4,905,842
Debt Conversion, Converted Instrument, Amount													$ 1,962,060	$ 1,897,000
Debt Conversion, Converted Instrument, Shares Issued \| shares													13,080,393	12,647,077
Other Noncash Expense													$ 318,000
May 2011 Note Financing [Member] \| Exchange Agreements [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares														37,600,000
Other Noncash Expense														$ 1,300,000
Issuance of notes											$ 0		0	$ 3,200,000						$ 0
Warrants To Purchase Of Common Stock \| shares														3,600,000
Surrendering Of Warrants To Purchase Of Coomon Stock \| shares														22,400,000
October 2011 Note Financing [Member]
Convertible Notes Payable											$ 58,824		$ 58,824	$ 1,341,738						$ 58,824
Debt Instrument Purchase Price								$ 50,000
Debt Instrument Discount Percentage								15.00%
Debt Instrument, Payment Terms								Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the October 2011 offering,
Debt Instrument, Convertible, Conversion Price \| $ / shares								$ 0.15			$ 0.15		$ 0.15							$ 0.15
Investors Minimum Beneficially Ownership Percentage								4.99%
Change In Fair Value Of Embedded Conversion Option and Warrants								$ 987,439
Debt Conversion, Converted Instrument, Shares Issued \| shares													8,183,333
Issuance of notes								400,000			$ 1,200,000		$ 1,200,000							$ 1,200,000
Long-term Debt, Gross								59,000			54,824		54,824							54,824
Original Issue Discount, net of accreted interest											984,733		$ 984,733	2,705						984,733
October 2011 Note Financing [Member] \| Exchange Agreements [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares													1,300,000
Other Noncash Expense													$ 530,000
Issuance of notes											1,000,000		$ 1,000,000							1,000,000
Warrants To Purchase Of Common Stock \| shares													12,100,000
Surrendering Of Warrants To Purchase Of Coomon Stock \| shares													6,000,000
October 2011 Note Financing [Member] \| Investor [Member]
Convertible Notes Payable								2,300,000
Debt Instrument Purchase Price								$ 2,000,000
December 2011 Note Financing [Member]
Convertible Notes Payable						$ 1,232,000					$ 131,928		$ 131,928	0						$ 131,928
Debt Instrument Purchase Price						$ 1,000,000
Debt Instrument Discount Percentage						15.00%
Debt Instrument, Payment Terms						Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the December 2011 offering.
Debt Instrument, Convertible, Conversion Price \| $ / shares						$ 0.15					$ 0.15		$ 0.15							$ 0.15
Percentage Of Common Stock Issuable Upon Conversion						50.00%
Debt Instrument, Maturity Date						Jan. 09, 2013
Investors Minimum Beneficially Ownership Percentage						4.99%
Change In Fair Value Of Embedded Conversion Option and Warrants						$ 586,376
Debt Conversion, Converted Instrument, Amount													$ 828,000
Debt Conversion, Converted Instrument, Shares Issued \| shares													5,516,666
Other Noncash Expense													$ 205,000
December 2011 Note Financing [Member] \| Exchange Agreements [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares													2,500,000
Issuance of notes											$ 215,000		$ 215,000							$ 215,000
Warrants To Purchase Of Common Stock \| shares													1,300,000
Surrendering Of Warrants To Purchase Of Coomon Stock \| shares													2,900,000
May 2012 Note Financing [Member]
Convertible Notes Payable	953,333										588,313		$ 588,313	0						588,313
Debt Instrument Purchase Price	$ 715,000
Debt Instrument Discount Percentage	25.00%
Debt Instrument, Convertible, Conversion Price \| $ / shares	$ 0.15
Percentage Of Common Stock Issuable Upon Conversion	50.00%
Debt Instrument, Maturity Date	May 18, 2013
Other Noncash Expense	$ 133,634
Senior Convertible Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares									768,633
Long-term Debt, Gross																													$ 88,824
Interest Payable \| L																														L 26,471
December To April Maturity Notes [Member]
Long-term Debt, Gross														479,000
Increase In Interest In Consideration For Conversion														$ 25,208
Additional Warrants In Consideration For Conversion \| shares														816,000
Fair Value Of Interest and Additional Warrants Issued														$ 87,000
August To October Maturity Notes [Member]
Long-term Debt, Gross														$ 318,000
Additional Warrants In Consideration For Conversion \| shares														730,000
Fair Value Of Interest and Additional Warrants Issued														$ 80,000
Repayments of Debt														$ 99,000
Junior Convertible Subordinated Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares														$ 0.15
Debt Conversion, Converted Instrument, Amount														$ 1,300,000
Long-term Debt, Gross											$ 186,000		$ 186,000	756,000						$ 186,000
Original Issue Discount, net of accreted interest														45,000
Repayments of Debt														530,000
Long-term Debt														711,701
Debt Instrument, Maturity Date Range, Start													Oct. 19, 2011
Debt Instrument, Maturity Date Range, End													May 12, 2012
Junior Convertible Subordinated Convertible Notes [Member] \| Minimum [Member]
Debt Instrument Discount Percentage											10.00%		10.00%							10.00%
Junior Convertible Subordinated Convertible Notes [Member] \| Maximum [Member]
Debt Instrument Discount Percentage											15.00%		15.00%							15.00%
Jmj Financial [Member]
Convertible Notes Payable											$ 73,590		$ 73,590	570,802						$ 73,590
Magna [Member]
Convertible Notes Payable											333,086		333,086	0						333,086
Asher [Member]
Convertible Notes Payable											$ 150,687		$ 150,687	$ 0						$ 150,687

NOTES PAYABLE-OFFICER: (Details Textual) - USD ($)	1 Months Ended				7 Months Ended	12 Months Ended		128 Months Ended
NOTES PAYABLE-OFFICER: (Details Textual) - USD ($)	Oct. 28, 2011	Mar. 17, 2011	Feb. 15, 2010	Sep. 22, 2008	Dec. 31, 2009	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Oct. 19, 2012	Sep. 27, 2012	Sep. 25, 2012	Sep. 19, 2012	Sep. 11, 2012	Aug. 02, 2012	Jul. 21, 2012	May 14, 2012	Dec. 31, 2011	May 31, 2011	Dec. 17, 2003
Proceeds from notes payable					$ 6,000,000	$ 250,000	$ 0	$ 250,000
Repayments of Debt	$ 400,000
Long-term Debt, Gross						$ 400,075	50,000	400,075	$ 132,500	$ 25,000	$ 100,000	$ 132,500	$ 103,500	$ 66,667	$ 250,000	$ 953,333	$ 50,000	$ 59,000	$ 40,000
Moore Notes [Member]
Debt Instrument, Interest Rate During Period						12.00%
Proceeds from notes payable		$ 6,000,000	$ 6,000,000	$ 6,000,000		$ 74,500
Repayments of Debt		200,000	$ 200,000			35,000
Long-term Debt, Gross		$ 230,000				477,000		477,000
Interest Expense, Debt						$ 29,695	$ 78,077	$ 300,022
Moore Notes [Member] \| Minimum [Member]
Long-term Debt, Gross				800,000
Moore Notes [Member] \| Maximum [Member]
Long-term Debt, Gross				$ 950,000

NOTES PAYABLE-OTHER: (Details Textual) - USD ($)		1 Months Ended
NOTES PAYABLE-OTHER: (Details Textual) - USD ($)	May 09, 2011	Jul. 21, 2012	Dec. 29, 2011	Oct. 28, 2011	Oct. 31, 2012	Oct. 19, 2012	Sep. 27, 2012	Sep. 25, 2012	Sep. 19, 2012	Sep. 11, 2012	Aug. 02, 2012	May 14, 2012	Dec. 31, 2011	Oct. 31, 2011	May 31, 2011	Apr. 28, 2011	Dec. 17, 2003
Interest Related To Promissory Note		$ 23,000		$ 59,000
Long-term Debt, Gross		$ 250,000			$ 400,075	$ 132,500	$ 25,000	$ 100,000	$ 132,500	$ 103,500	$ 66,667	$ 953,333	$ 50,000	$ 50,000	$ 59,000		$ 40,000
Debt Instrument, Interest Rate, Stated Percentage		33.00%														8.00%
Debt Instrument, Maturity Date	May 12, 2012	Dec. 31, 2012	Jan. 09, 2015	Oct. 31, 2014
Issuance of notes		$ 250,000			$ 400,075

DERIVATIVES (Details) - USD ($)	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2010	Jul. 31, 2010	Apr. 30, 2010	Jan. 31, 2010	Oct. 31, 2009
Principal	$ 2,315,202	$ 1,739,224	$ 5,482,364	$ 6,294,923	$ 8,976,071	$ 8,166,355	$ 2,931,384	$ 1,991,267	$ 777,154
Original Issue Discount	4,541	26,523	456,547	1,025,966	1,300,347	1,312,241	89,239	120,269	21,937
Warrant Liability	434,136	1,265,985	3,090,088	5,527,591	6,391,071	7,936,668	15,908,302	8,520,828	13,006,194
Embedded Derivatives Liability at October 31, 2012	0	2,136	137,749	741,496	946,046	1,086,599	1,058,580	229,625	81,028
Other outstanding warrants [Member]
Principal													$ 0
Original Issue Discount													0
Warrant Liability													12,785,695
Embedded Derivatives Liability at October 31, 2012													0
Change in fair value [Member]
Warrant Liability	(868,133)	(1,703,252)	(2,302,707)	(923,052)	(2,174,948)	(6,826,019)	4,915,676	(3,789,889)
Embedded Derivatives Liability at October 31, 2012	(2,136)	(20,567)	(438,054)	159,657	(416,347)	(2,141,984)	763,523	(51,972)
Accreted Interest [Member]
Principal											$ 0	$ 0	0
Original Issue Discount	(21,984)	(229,392)	(569,419)	(532,559)	(471,290)	(340,050)	(74,422)	(73,363)			(251,188)	(225,321)	(123,846)
Warrant Liability											0	0	0
Embedded Derivatives Liability at October 31, 2012											0	0	$ 0
Bridge Note I- Extension of Maturity Date [Member]
Principal												0
Original Issue Discount												0
Warrant Liability												202,500
Embedded Derivatives Liability at October 31, 2012												103,400
Exercise of Common Stock Warrants [Member]
Principal										$ 0	0	0
Original Issue Discount										0	0	0
Warrant Liability										(1,475,758)	(1,790,823)	(1,702,073)
Embedded Derivatives Liability at October 31, 2012										0	0	$ 0
Bridge Note V [Member]
Principal											640,307
Original Issue Discount											97,807
Warrant Liability											229,619
Embedded Derivatives Liability at October 31, 2012											271,554
Note Payoffs [Member]
Principal					(155,806)	(26,316)	(159,675)	(187,582)	(414,118)	(88,236)	(1,040,177)
Original Issue Discount									0		(4,222)
Warrant Liability									0		0
Embedded Derivatives Liability at October 31, 2012						(8,860)	(5,904)		(46,945)	(12,665)	$ (64,354)
Issuance of Optimus Warrants
Principal										0
Original Issue Discount										0
Warrant Liability										6,856,946
Embedded Derivatives Liability at October 31, 2012										0
Bridge Note Conversions [Member]
Principal				(169,000)	(221,788)	(1,164,947)				(2,420,373)
Original Issue Discount										0
Warrant Liability										0
Embedded Derivatives Liability at October 31, 2012				0	(10,530)	(381,209)				$ (701,718)
Exercise Of Warrants [Member]
Principal									0
Original Issue Discount									0
Warrant Liability							(639,960)	(1,382,847)	(4,156,797)
Embedded Derivatives Liability at October 31, 2012									0
Issuance Of Warrants [Member]
Principal									0
Original Issue Discount									0
Warrant Liability							2,990,520	35,523	1,042,559
Embedded Derivatives Liability at October 31, 2012									0
Bridge Note VI [Member]
Principal									265,457
Original Issue Discount									25,457
Warrant Liability									72,300
Embedded Derivatives Liability at October 31, 2012									$ 39,416
Issuance of November 2010 Bridge Notes [Member]
Principal								931,579
Original Issue Discount								96,579
Warrant Liability								391,076
Embedded Derivatives Liability at October 31, 2012								150,156
Exchange of November 2010 Bridge Notes [Member]
Principal								17,175
Original Issue Discount								17,175
Warrant Liability								86,963
Embedded Derivatives Liability at October 31, 2012								9,389
Issuance of January 2011 Bridge Notes [Memebr]
Principal								452,941
Original Issue Discount								57,941
Warrant Liability								173,808
Embedded Derivatives Liability at October 31, 2012								$ 41,024
Issuance of Q2 2011 Bridge Notes [Member]
Principal							473,392
Original Issue Discount							43,392
Warrant Liability							121,238
Embedded Derivatives Liability at October 31, 2012							71,336
Issuance of Q3 2011 Bridge Notes [Member]
Principal						11,765
Original Issue Discount						1,765
Warrant Liability						4,968
Embedded Derivatives Liability at October 31, 2012						5,051
Issuance of May 2011 Notes [Member]
Principal						7,077,936
Original Issue Discount						1,553,254
Warrant Liability						0
Embedded Derivatives Liability at October 31, 2012						2,719,345
Additional warrants issued to Bridge Note holder [Member]
Warrant Liability						36,376
Exchange Of Bridge Notes [Member]
Principal			52,941			8,033
Original Issue Discount						8,033
Warrant Liability			0
Embedded Derivatives Liability at October 31, 2012						2,656
Conversion of May 2011 Notes [Member]
Principal			(38,000)	(1,924,060)	(1,225,561)	(671,500)
Embedded Derivatives Liability at October 31, 2012			(5,016)	(341,342)	(110,494)	(166,980)
Exchanges/Exercises of October 2007 Warrants [Member]
Warrant Liability						$ (1,186,959)
Issuance of October 2011 Notes [Member]
Principal					2,326,471
Original Issue Discount					459,396
Warrant Liability					0
Embedded Derivatives Liability at October 31, 2012					396,818
Issuance Of Long Term Convertible Promissory Notes [Member]
Principal					86,400		626,400
Embedded Derivatives Liability at October 31, 2012							$ 0
Exchange Of Warrants [Member]
Warrant Liability			(134,796)	59,572	$ 816,259
Partial Note Repayments [Member]
Principal				(52,941)
Conversion Of December 2011 Notes [Member]
Principal			(827,500)
Embedded Derivatives Liability at October 31, 2012			$ (160,677)
Issuance of May 2012 Notes [Member]
Principal		953,333
Warrant Liability		291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes [Member]
Principal		(4,473,673)
Original Issue Discount		(200,632)
Embedded Derivatives Liability at October 31, 2012		(115,046)
Debt for Equity Exchange: Bridge Notes [Member]
Principal		(50,000)
Warrant Liability		(4,750)
July 2012Exchange of Warrants [Member]
Warrant Liability		(407,501)
JMJ Settlement Agreement [Member]
Principal		540,000
JMJ Note Conversions [Member]
Principal		$ (712,800)
Conversion Of October 2011 Notes [Member]
Principal				(1,227,500)
Embedded Derivatives Liability at October 31, 2012				(329,433)
Conversion Of Long Term Convertible Promissory Notes [Member]
Principal				(540,000)
Issuance Of December 2011 Notes [Member]
Principal				1,232,353
Original Issue Discount				258,178
Warrant Liability				0
Embedded Derivatives Liability at October 31, 2012				$ 306,568
Issuance Of Patton Note [Member]
Principal	66,667
Warrant Liability	13,311
Issuance Of French Note [Member]
Principal	25,000
Warrant Liability	4,565
Issuance Of Paterson Note [Member]
Principal	100,000
Warrant Liability	18,258
Issuance Of Hanover September Note [Member]
Principal	132,500
Issuance Of Asher Note [Member]
Principal	103,500
Issuance Of Hanover October Note [Member]
Principal	132,500
Issuance Of Jmj Note [Member]
Principal	100,000
Assignment Of Notes To Magna [Member]
Principal	(384,264)
New Magna Note (result of above assignment) [Member]
Principal	400,075
Magna Conversions [Member]
Principal	(100,000)
Additional Warrants Issued Due To Investors Due To Anti Dilution Provision [Member]
Warrant Liability	$ 150

DERIVATIVES (Details 1) - $ / shares

12 Months Ended

Oct. 31, 2012

Oct. 31, 2011

May 14, 2012

Dec. 31, 2011

Dec. 29, 2011

Oct. 28, 2011

Apr. 04, 2011

Mar. 17, 2011

Sep. 28, 2010

Jan. 11, 2010

Exercise Price

$ 0.15

$ 0.1952

$ 0.15

$ 0.17

$ 0.20

Amount

38,784,491

49,400,000

Minimum [Member]

Exercise Price

$ 0.15

0.15

$ 0.15

Maximum [Member]

Exercise Price

0.155

0.1952

$ 0.17

Common Stock Purchase Warrant [Member] | July 2012 Warrant Exchanges [Member]

Exercise Price

$ 0.15

Amount

34,791,156

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | August 2007 Notes [Member]

Exercise Price

$ 0.15

Amount

287,001

Expiration Date

August 2012

Common Stock Purchase Warrant [Member] | May 2011 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

23,593,122

Expiration Date

May 2015

May 2014

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

1,453,553

7,754,902

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member] | Minimum [Member]

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member] | Maximum [Member]

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | May 2012 Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

3,578,949

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Bridge Notes [Member]

Amount

24,754,595

22,630,101

Common Stock Purchase Warrant [Member] | Bridge Notes [Member] | Minimum [Member]

Exercise Price

$ 0.035624

$ 0.15

Expiration Date

January 2013

Common Stock Purchase Warrant [Member] | Bridge Notes [Member] | Maximum [Member]

Exercise Price

$ 0.17

Expiration Date

April 2015

Common Stock Purchase Warrant [Member] | Vendor & Other [Member]

Exercise Price

$ 0.15

Amount

46,956

446,956

Expiration Date

February 2012

Common Stock Purchase Warrant [Member] | Vendor & Other [Member] | Minimum [Member]

Expiration Date

0.15

Common Stock Purchase Warrant [Member] | Vendor & Other [Member] | Maximum [Member]

Expiration Date

1952

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member]

Exercise Price

$ 0.15

Amount

3,735,430

2,804,776

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member] | Minimum [Member]

Expiration Date

May 2014

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member] | Maximum [Member]

Expiration Date

May 2017

November 2015

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member]

Amount

1,410,938

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member] | Minimum [Member]

Exercise Price

$ 0.053

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | August and September Convertible Promissory Notes [Member] | Maximum [Member]

Exercise Price

$ 0.15

Expiration Date

August 2017

Common Stock Purchase Warrant [Member] | Subtotal [Member]

Amount

74,762,588

112,281,857

Expiration Date

Common Stock Purchase Warrant [Member] | Preferred Stock Agreement (4/04/2011) [Member]

Amount

^[1]

25,560,000

Expiration Date

April 2014

Common Stock Purchase Warrant [Member] | Grand Total [Member]

Amount

100,322,588

137,841,857

Expiration Date

Common Stock Purchase Warrant [Member] | Executive Officer [Member]

Exercise Price

$ 0.15

Amount

7,674,512

Expiration Date

August 2014

Common Stock Purchase Warrant [Member] | 2007 Securities Purchase Agreement [Member] | Minimum [Member]

Expiration Date

August 2012

August

Common Stock Purchase Warrant [Member] | 2007 Securities Purchase Agreement [Member] | Maximum [Member]

Expiration Date

October 2012

[1]	During December 2011, the Company unreserved for issuance shares related to the Optimus warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

DERIVATIVES (Details 2) - $ / shares	12 Months Ended
DERIVATIVES (Details 2) - $ / shares	Oct. 31, 2012	Oct. 31, 2011
Stock Price:	$ 0.045	$ 0.141
Volatility %	66.51%	60.23%
Risk Free Rate:	0.09%	0.09%
Minimum [Member]
Exercise Price:	$ 0.053	$ 0.15
Expected term: (Days)	81 days	289 days
Volatility %	66.51%	60.23%
Risk Free Rate:	0.09%	0.09%
Maximum [Member]
Exercise Price:	$ 0.17	$ 0.17
Expected term: (Days)	1736 days	1219 days
Volatility %	146.78%	163.40%
Risk Free Rate:	0.72%	0.56%

DERIVATIVES (Details Textual) - USD ($)				12 Months Ended		128 Months Ended
DERIVATIVES (Details Textual) - USD ($)	Jul. 05, 2012	Jun. 08, 2012	Apr. 04, 2011	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Dec. 06, 2012	Aug. 27, 2012	May 14, 2012	Jan. 31, 2012	Dec. 31, 2011	Dec. 29, 2011	Oct. 28, 2011	May 09, 2011	Apr. 28, 2011	Mar. 17, 2011	Oct. 31, 2010	Sep. 28, 2010	Jan. 11, 2010
Class of Warrant or Right, Outstanding				38,784,491		38,784,491												49,400,000
Exercises Of Warrants				$ 2,745,097
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.15	$ 0.15	$ 0.1952	$ 0.15			$ 0.15		$ 0.15	$ 0.15	$ 0.15			$ 0.15		$ 0.17	$ 0.20
Proceeds from the exercise of warrants				$ 411,765	$ 1,085,001	$ 1,666,766
Common stock, par value (in dollars per share)				$ 0.001	$ 0.001	$ 0.001									$ 0.001
Warrants Purchased During Period			25,560,000	2,352,940
Common Stock Issued Upon Exchange of Warrants				$ 223,596	$ 1,533,965
Other Noncash Income					36,000
Debt Instrument, Convertible, Conversion Price				$ 0.15		$ 0.15	$ 0.03	$ 0.15	$ 0.15	$ 0.15	$ 0.15	$ 0.15		$ 0.15	$ 0.15		$ 0.15
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013				$ 0	946,046	$ 0
Warrants Subject To Anti Dilution Provisions				13,100,000
Anti Dilution Provisions Additional Warrants Issuable				42,400
Anti Dilution Provisions Additional Warrants Exercise Price				$ 0.1495
Exercise Price One [Member]
Anti Dilution Provisions Additional Warrants Exercise Price				0.1495
Exercise Price Two [Member]
Anti Dilution Provisions Additional Warrants Exercise Price				$ 0.10
Common Stock [Member]
Purchase Of Shares				10,000,000		10,000,000
Common Stock Issued Upon Exchange of Warrants				$ 1,597	$ 5,841
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.15	$ 0.15	$ 0.15												0.15
Probability Of Exercise Of Additional Warrants At Exercise Price One				40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two				60.00%
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.155	$ 0.1952	$ 0.155												$ 0.17
Probability Of Exercise Of Additional Warrants At Exercise Price One				50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two				50.00%
Warrant Liability [Member]
Class of Warrant or Right, Outstanding				85,200,000		85,200,000
Exchanges Of Warrants				$ 34,800,000
Reduction In Warrant Outstanding Subject To Anti Dilution Provision				13,100,000
Fair Value of Attached Warrants at issuance				434,000		$ 434,000
Servicing Liability at Fair Value, Other Changes in Fair Value				$ 6,400,000	$ 7,800,000
Warrant Equity [Member]
Class of Warrant or Right, Outstanding				15,100,000		15,100,000
2011 Warrant Exchange [Member]
Common stock, par value (in dollars per share)				$ 0.001		$ 0.001
Warrants Purchased During Period				4,791,337
Non Cash Warrant Expenses				$ 25,000
Common Stock Issued Upon Exchange of Warrants				1,597,112
Other Noncash Income				$ 54,000
2011 Warrant Exchange [Member] \| Common Stock [Member]
Warrants Purchased During Period				6,388,449
Non Cash Warrant Expenses				$ 89,000
July 2012 Warrant Exchange [Member]
Exchanges Of Warrants	$ 34,791,156
Warrants Purchased During Period	23,726,545	11,064,611
Other Noncash Income	$ 408,000
Debt Instrument, Convertible, Type of Equity Security		800,000
Investment Warrants Expiration Date		Aug. 16, 2012
Warrants With Anti Dilution Provisions [Member]
Reduction In Warrant Outstanding Subject To Anti Dilution Provision				$ 13,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.035		0.035
Issuance Of Additional Warrants				$ 833,000
Debt Instrument, Convertible, Conversion Price				$ 0.053		$ 0.053
Warrants With Anti Dilution Provisions [Member] \| Common Stock [Member]
Class of Warrant or Right, Outstanding				65,531,432		65,531,432
Purchase Of Shares				34,791,156		34,791,156
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Fair Value, Gross Liability				$ 1,900,000	6,400,000	$ 1,900,000
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013				0	946,000	$ 0
Servicing Liability at Fair Value, Other Changes in Fair Value				6,000,000	$ 9,800,000
October 2007 warrants [Member]
Exchanges Of Warrants				400,000
Reduction In Warrant Outstanding Subject To Anti Dilution Provision				$ 15,869,507

STOCK OPTIONS : (Details) - USD ($)	1 Months Ended	12 Months Ended
STOCK OPTIONS : (Details) - USD ($)	Jul. 21, 2009	Oct. 31, 2012	Oct. 31, 2011
Outstanding Number of Shares		27,317,424	26,467,424
Granted Number of Shares		17,540,000	850,000
Cancelled or Expired In shares		(50,000)	0
Outstanding Number of Options		44,807,424	27,317,424
Vested & Exercisable Number of Shares		29,278,169
Outstanding Weighted-Average Exercise Price		$ 0.16	$ 0.16
Granted Weighted-Average Exercise Price		0.15	0.12
Cancelled or Expired Weighted Average Exercise Price		0.10	0
Outstanding Weighted-Average Exercise Price		0.16	$ 0.16
Vested & Exercisable Weighted-Average Exercise Price		$ 0.16
Outstanding Weighted Average Remaining Contractual Life In Years		8 years 1 month 6 days	7 years 4 months 24 days
Granted Weighted Average Remaining Contractual Life In Years		9 years	9 years 2 months 12 days
Cancelled or Expired Weighted Average Remaining Contractual Life In Years		6 years 9 months	0 years
Outstanding Weighted Average Remaining Contractual Terms			8 years 1 month 6 days
Vested & Exercisable Weighted Average Remaining Contractual Life In Years	6 months	5 years 9 months
Outstanding Aggregate Intrinsic Value		$ 367,417	$ 415,967
Granted Aggregate Intrinsic Value		0	15,200
Cancelled or Expired Aggregate Intrinsic Value		0	0
Outstanding Aggregate Intrinsic Value		0	$ 367,417
Vested & Exercisable Aggregate Intrinsic Value		$ 0

STOCK OPTIONS : (Details 1)	12 Months Ended
STOCK OPTIONS : (Details 1)	Oct. 31, 2012	Oct. 31, 2011
Volatility:	143.00%	150.44%
Days to Maturity:	10 years	10 years
Dividend yield	0.00%	0.00%
Risk-free Rate:	2.10%	3.50%
Forfeiture Rate	4.40%	4.40%

STOCK OPTIONS : (Details Textual) - USD ($)		1 Months Ended		12 Months Ended		128 Months Ended
STOCK OPTIONS : (Details Textual) - USD ($)	Jun. 06, 2006	Jul. 21, 2009	Nov. 30, 2004	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Aug. 13, 2012	Sep. 27, 2011	Oct. 31, 2010	Oct. 31, 2009
Common Stock, Capital Shares Reserved for Future Issuance				5,000,000		5,000,000
Vested & Exercisable Weighted Average Remaining Contractual Life In Years		6 months		5 years 9 months
Common stock, shares authorized				1,000,000,000	1,000,000,000	1,000,000,000	45,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date				85.00%
Proceeds from Stock Plans				$ 18,300
Granted Weighted-Average Exercise Price				$ 0.15	$ 0.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				44,807,424	27,317,424	44,807,424			26,467,424	18,331,591
Non-cash charges to consultants and employees for options and stock				$ 1,146,843	$ 795,226	$ 4,980,046
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value				2,539,792	103,125
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options					2,047,000
Research and Development Expense [Member]
Non-cash charges to consultants and employees for options and stock				480,000	272,000
General and Administrative Expense [Member]
Non-cash charges to consultants and employees for options and stock				$ 610,000	$ 379,000
Employees and Consultants [Member]
Options granted to consultants and professionals (in shares)				17,540,000
Granted Weighted-Average Exercise Price				$ 0.15
Two Thousand and Four Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent			85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				2,381,525		2,381,525
Two Thousand and Five Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				5,444,000		5,444,000
Two Thousand and Nine Stock Option Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance		20,000,000
Vested & Exercisable Weighted Average Remaining Contractual Life In Years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				19,441,899		19,441,899
Two Thousand and Eleven Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance								20,000,000

COMMITMENTS AND CONTINGENCIES : (Details Textual) - USD ($)								1 Months Ended									10 Months Ended	12 Months Ended
	Jun. 13, 2012	Apr. 04, 2011	Oct. 14, 2010	May 10, 2010	Mar. 29, 2006	Mar. 07, 2005	Mar. 01, 2005	Aug. 31, 2012	Jul. 24, 2012	May 31, 2012	Jul. 31, 2011	Apr. 30, 2011	Jul. 31, 2009	Jul. 21, 2009	Nov. 30, 2007	Feb. 15, 2007	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2007	Dec. 12, 2011	Aug. 19, 2011
Option Exercise Fee Payable																						$ 20,000
Stock issued																	$ 235,000	$ 0	$ 1,676,554	$ 6,828,293	$ 9,380,902
Stock Issued (in shares)								4,076,923		4,000,000							40,000				59,228,334
Stock Price:																		$ 0.045	$ 0.141
Payments for Leasing Costs		$ 16,000										$ 21,000
Cost of Utilities												7,200
Cost Of Utilities Per R E												$ 10,700
Operating Leases, Rent Expense											$ 54,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																		2 years
Granted Number of Shares																		17,540,000	850,000
Granted Weighted-Average Exercise Price																		$ 0.15	$ 0.12
Common stock, shares issued																		394,804,165	250,173,570				768,633
Other Noncash Income																			$ 36,000
Mr.Moore [Member]
Increase Decrease In Officer Compensation																		$ 350,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant															1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period															750,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 month 24 days															24 months
Granted Number of Shares																		1,500,000
Granted Weighted-Average Exercise Price																		$ 0.40
Dr.Rothman [Member]
Granted Weighted-Average Exercise Price			$ 0.15											$ 0.10		$ 0.165
Officers' Compensation						$ 305,000
Officer Compensation Payable In Cash						275,000
Officer Compensation Payable In Stock						$ 30,000
Investment Options, Expiration Date					Mar. 29, 2016		Mar. 01, 2015							Jul. 21, 2019		Feb. 15, 2017
Vested Option Percentage							75.00%
Pennsylvania [Member]
Option Exercise Fee Payable				$ 35,000
Stock issued				$ 70,000
Stock Issued (in shares)				388,889
Stock Price:				$ 0.18
Historical Patent Costs				$ 462,000
Licenses Revenue																		$ 517,000
Non Cash Income				223,620
Total Project Agreement Cost													$ 12,200,000
Numoda [Member]
Stock issued				$ 350,000
Stock Issued (in shares)	15,000,000			3,500,000					24,058,407
Due from Affiliates																		7,400,000
Other Noncash Income	$ 869,000								$ 618,000
Purchase Price Per Share	$ 0.15
Cancellation Of Accounts Receivables	$ 2,250,000
Accounts Payable																		$ 858,000
Stipulation For Settlement Claim	On July 24, 2012, the Circuit Court of the 11th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which we refer to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which we refer to as the Stipulation, provide for the full and final settlement of Socius''s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which we refer to as the Claim. Socius purchased approximately $1.8 million of the Claim against us from Numoda Corporation.
Clinical Trail Services Settlement Claim									2,888,860
Settlement Claim									1,800,000
Settlement Claim Towards Transaction Related Costs									$ 1,000,000

INCOME TAXES: (Details) - USD ($)	12 Months Ended
INCOME TAXES: (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Federal
Current	$ 0	$ 0
Deferred	(9,974,596)	(1,292,094)
State and Local
Current	(346,787)	(379,472)
Deferred	(1,826,038)	(81,597)
Change in valuation allowance	11,800,634	1,373,691
Income tax provision (benefit)	$ (346,787)	$ (379,472)

- Definition

The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted federal tax law to the domestic taxable Income or Loss from continuing operations.

+ References

+ Details

- Definition

The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable Income or Loss from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law.

+ References

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) in the entity's state and local deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the applicable enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 8, 16, 17, 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

+ Details

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45, 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

INCOME TAXES: (Details 1) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Deferred Tax Assets
Deferred Tax Assets, Operating Loss Carryforwards	$ 21,162,237	$ 12,994,244
Stock-based compensation	1,907,607	1,474,016
Others	957,982	48,470
Total deferred tax assets	24,027,826	14,516,730
Valuation allowance	(22,414,639)	(10,614,005)
Deferred tax asset, net of valuation allowance	1,613,187	3,902,725
Deferred Tax Liabilities
Valuation of warrants	0	(3,241,085)
Other deferred tax liabilities	(1,613,187)	(661,640)
Total deferred tax liabilities	(1,613,187)	(3,902,725)
Net deferred tax asset (liability)	$ 0	$ 0

INCOME TAXES: (Details 2)	12 Months Ended
INCOME TAXES: (Details 2)	Oct. 31, 2012	Oct. 31, 2011
US Federal statutory rate	(34.00%)	(34.00%)
State income tax, net of federal benefit	(5.90%)
Fair value of common stock warrant liability	(15.00%)
Deferred tax adjustment	(39.30%)
Change in valuation allowance	97.80%	16.90%
Other permanent differences	(6.50%)	12.60%
Income tax provision (benefit)	(2.90%)	(4.50%)

INCOME TAXES : (Details Textual) - USD ($)	12 Months Ended
INCOME TAXES : (Details Textual) - USD ($)	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Feb. 28, 2011
Net Cash Received Amount On Net Operating Losses	$ 346,787	$ 379,472		$ 379,742
Sale Of Net Operating Losses		725,000	$ 725,000
Valuation Allowance, Deferred Tax Asset, Change in Amount	11,800,634	1,373,691
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	55,127,000	32,485,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 26,880,000	$ 12,593,000

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References + Details

SHAREHOLDERS' EQUITY : (Details Textual) - USD ($)		1 Months Ended						2 Months Ended	10 Months Ended	12 Months Ended				128 Months Ended
SHAREHOLDERS' EQUITY : (Details Textual) - USD ($)	Apr. 04, 2011	Aug. 31, 2012	May 31, 2012	Oct. 28, 2011	Apr. 30, 2011	Jul. 31, 2010	Jul. 19, 2010	Dec. 31, 2011	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2008	Oct. 31, 2007	Oct. 31, 2012	Jul. 21, 2012	May 14, 2012	Dec. 29, 2011	Apr. 28, 2011	Mar. 17, 2011	Sep. 28, 2010	Jan. 11, 2010
Preferred stock, shares authorized										5,000,000	5,000,000			5,000,000
Debt Instrument, Interest Rate, Stated Percentage															33.00%			8.00%
Stock Issued (in shares)		4,076,923	4,000,000						40,000				59,228,334
Repayments of Debt				$ 400,000
Warrants Exercised During Period											77,019,962
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15			$ 0.15				$ 0.15		$ 0.15	$ 0.1952			$ 0.15		$ 0.15	$ 0.15		$ 0.15	$ 0.17	$ 0.20
Class of Warrant or Right, Outstanding										38,784,491				38,784,491						49,400,000
Liquidation preference										$ 9,722,570	$ 9,722,570			$ 9,722,570
Preferred Stock, Liquidation Preference Per Share										$ 10,000				$ 10,000
Preferred Stock, Amount of Preferred Dividends in Arrears										$ 1,538,686	740,000			$ 2,322,570
Notes Payable											13,049,210
Preferred Stock redeemed											3,051,000
Promissory Note Receivable										10,484,022	10,283,510			10,484,022
Note receivable in connection with exercise of warrants										$ 0	2,389,500			$ 9,998,210
Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage										2.00%				2.00%
Accrued Interest On Promissory Note										$ 485,812	$ 285,300
Optimus
Class Of Options Or Right Number Of Securities Called By Options Or Rights					25,560,000	40,500,000
Exercise Price Of Options					$ 0.15	$ 0.25
Percentage Of Warrant Vest and Exercisable						135.00%
Warrants Exercised During Period						15,752,903
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.15
Class of Warrant or Right, Outstanding							0.155			25,560,000	25,560,000			25,560,000
Warrants Unreserved For Issuance								25,560,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.15	$ 0.15			$ 0.15						$ 0.15
Minimum [Member] \| Optimus
Class of Warrant or Right, Exercise Price of Warrants or Rights											0.15
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										0.155	0.1952			0.155						0.17
Maximum [Member] \| Optimus
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.20
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.01				$ 0.01						$ 0.15
Class of Warrant or Right, Outstanding										55,000,000				55,000,000						49,400,000
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.15				$ 0.15							0.17
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.035624				$ 0.035624							$ 0.20
Common Stock [Member]
Closing Sale Price Percentage										90.00%				90.00%
Outstanding Stock Percentage										10.00%				10.00%
Maintenance Costs										$ 15,000
Purchase Of Shares										10,000,000				10,000,000
Stock Issued (in shares)									40,000			211,853	59,228,334
Hanover Purchase Agreement [Member]
Stock Issued (in shares)										3,500,000
Series B Preferred Stock [Member]
Sale of Stock, Price Per Share	$ 10,000						$ 10,000			$ 10,000				$ 10,000
Preferred stock, shares authorized							7,500,000
Closing Sale Price Percentage							75.00%
Outstanding Stock Percentage							9.99%
Preferred Stock Shares Available For Sale	284									284				284
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Proceeds from Issuance of Debt											$ 1.47
Proceeds from Debt, Net of Issuance Costs											$ 1.34
Stock Issued (in shares)											177
Repayments of Debt											$ 300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.25
Preferred Stock redeemed (in shares)											226
Preferred Stock redeemed											$ 3,141,004
Stock Redeemed Or Called During Period Value Paid In Cash											76,622
Stock Redeemed Or Called During Period Value Paid In Extingushment Of Interest Debt Outstanding											3,051,000
Stock Redeemed Or Called During Period Value Paid In Extingushment Of Debt Outstanding											$ 13,382
Series B Preferred Stock [Member] \| Warrant [Member]
Additional Warrant In Percentage	135.00%
Stock Issued (in shares)	25,560,000						40,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15

FAIR VALUE (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Common Stock Warrant Liability	$ 434,136	$ 6,391,071
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013	0	946,046
May 2012 Notes [Member]
Common Stock Warrant Liability	588,313
Hanover PIPE Notes -September & October 2012 [Member]
Common Stock Warrant Liability	362,791
Magna Exchange Note [Member]
Common Stock Warrant Liability	333,086
Asher Note [Member]
Common Stock Warrant Liability	150,687
French, Patton & Paterson Notes [Member]
Common Stock Warrant Liability	208,664
Other Short-Term Notes Payable [Member]
Common Stock Warrant Liability	371,968
Short Term Convertible Notes and Fair Value Of Embedded Derivative [Member]
Common Stock Warrant Liability	2,015,509
Fair Value, Inputs, Level 1 [Member] \| May 2012 Notes [Member]
Common Stock Warrant Liability	0
Fair Value, Inputs, Level 1 [Member] \| Common Stock Warrant Liability [Member]
Common Stock Warrant Liability	0
Fair Value, Inputs, Level 3 [Member] \| May 2012 Notes [Member]
Common Stock Warrant Liability	588,313
Fair Value, Inputs, Level 3 [Member] \| Hanover PIPE Notes -September & October 2012 [Member]
Common Stock Warrant Liability	362,791
Fair Value, Inputs, Level 3 [Member] \| Magna Exchange Note [Member]
Common Stock Warrant Liability	333,086
Fair Value, Inputs, Level 3 [Member] \| Asher Note [Member]
Common Stock Warrant Liability	150,687
Fair Value, Inputs, Level 3 [Member] \| French, Patton & Paterson Notes [Member]
Common Stock Warrant Liability	208,664
Fair Value, Inputs, Level 3 [Member] \| Common Stock Warrant Liability [Member]
Common Stock Warrant Liability	$ 434,136
Fair Value, Inputs, Level 3 [Member] \| Embedded Derivative Liability [Member]
Common Stock Warrant Liability		6,391,071
Embedded derivative liability, convertible at $0.15 from May 2012 through January 2013		$ 946,046

FAIR VALUE (Details 1) - USD ($)	3 Months Ended								12 Months Ended
FAIR VALUE (Details 1) - USD ($)	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2012	Oct. 31, 2011
Exercises Of Warrants									$ 2,745,097
Embedded Derivative Liability [Member]
Beginning balance				$ 946,046				$ 81,028	946,046	$ 81,028
Debt for Equity Exchange: Bridge Notes									(115,046)	(190,449)
Note Conversions and Payoffs									(836,468)	(683,977)
Issuance of additional warrants due to anti-dilution provisions									306,568	3,505,605
Change in fair value									(301,100)	(1,766,161)
Ending Balance	$ 0				$ 946,046				0	946,046
Common Stock Warrant Liability [Member]
Beginning balance	1,265,985	$ 3,090,088	$ 5,527,591	6,391,071	7,936,668	$ 15,908,302	$ 8,520,828	13,006,194	6,391,071	13,006,194
Issuance of common stock warrants	36,134	291,400	0	0	0	41,344	3,111,758	600,407
Exercises and Exchanges of warrants		0		59,572		(1,186,959)		(1,295,884)
Reclassification of liabilities to equity		0
Debt for Equity Exchange: Bridge Notes		(4,750)				0
Exercises Of Warrants			0				(639,960)
Exchanges Of Warrants	0	(407,501)	(134,796)		816,259	0	0
Reclassification of warrant liability to equity	0				(186,908)
Issuance of additional warrants due to anti-dilution provisions	150				0
Change in fair value	(868,133)	(1,703,252)	(2,302,707)	(923,052)	(2,174,948)	(6,826,019)	4,915,676	(3,789,889)
Ending Balance	$ 434,136	$ 1,265,985	$ 3,090,088	$ 5,527,591	$ 6,391,071	$ 7,936,668	$ 15,908,302	$ 8,520,828	$ 434,136	$ 6,391,071

FAIR VALUE (Details 2) - USD ($)	12 Months Ended
FAIR VALUE (Details 2) - USD ($)	Oct. 31, 2012	Nov. 12, 2012	Jul. 21, 2012	Oct. 31, 2011
Issuance of notes	$ 400,075		$ 250,000
Common Stock Warrant Liability	434,136			$ 6,391,071
May 2012 Notes [Member]
Issuance of notes	687,000
Issuance of C/S warrants	(291,400)
Change in fair value	192,713
Common Stock Warrant Liability	588,313
Hanover PIPE Notes -September & October 2012 [Member]
Issuance of notes	265,000
Change in fair value	97,791
Common Stock Warrant Liability	362,791
Magna Exchange Note [Member]
Issuance of notes	400,075
Conversions to common stock	(100,000)
Change in fair value	33,011
Common Stock Warrant Liability	333,086
Asher Note [Member]
Issuance of notes	103,500	$ 153,500
Change in fair value	47,187
Common Stock Warrant Liability	150,687
French, Patton & Paterson Notes [Member]
Issuance of notes	175,000
Reclassification Of Warrants To Equity	(36,134)
Change in fair value	69,798
Common Stock Warrant Liability	$ 208,664

FAIR VALUE (Details Textual) - USD ($)	Oct. 31, 2012	May 14, 2012	Dec. 31, 2011	Dec. 29, 2011	Oct. 31, 2011	Oct. 28, 2011	Apr. 04, 2011	Mar. 17, 2011	Sep. 28, 2010	Jan. 11, 2010
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15	$ 0.15	$ 0.15	$ 0.15	$ 0.1952	$ 0.15	$ 0.15	$ 0.15	$ 0.17	$ 0.20
Original Issue Discount, net of accreted interest	$ (4,541)				$ (1,300,345)
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.15				$ 0.15				0.15
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.155				$ 0.1952				0.17
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.01								$ 0.15
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.15									0.17
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.035624									$ 0.20

SUBSEQUENT EVENTS (Details Textual) - USD ($)						1 Months Ended									10 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Feb. 12, 2013	Dec. 13, 2012	Dec. 06, 2012	Nov. 12, 2012	May 09, 2011	Jan. 17, 2013	Dec. 31, 2012	Dec. 26, 2012	Dec. 20, 2012	Aug. 31, 2012	Jul. 21, 2012	May 31, 2012	Dec. 29, 2011	Oct. 28, 2011	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2007	Dec. 21, 2012	Oct. 19, 2012	Sep. 27, 2012	Sep. 25, 2012	Sep. 19, 2012	Sep. 11, 2012	Aug. 27, 2012	Aug. 13, 2012	Aug. 02, 2012	May 14, 2012	Jan. 31, 2012	Dec. 31, 2011	May 31, 2011	Apr. 28, 2011	Apr. 04, 2011	Mar. 17, 2011	Sep. 28, 2010	Jan. 11, 2010	Dec. 17, 2003
Issuance of notes											$ 250,000					$ 400,075
Debt Instrument, Interest Rate, Stated Percentage											33.00%																						8.00%
Debt Instrument, Maturity Date					May 12, 2012						Dec. 31, 2012		Jan. 09, 2015	Oct. 31, 2014
Debt Instrument Purchase Price			$ 100,000										$ 1,000,000																$ 715,000				$ 2,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights													$ 0.15	$ 0.15		$ 0.15	$ 0.1952												$ 0.15		$ 0.15			$ 0.15	$ 0.15	$ 0.17	$ 0.20
Debt Instrument, Convertible, Conversion Price			$ 0.03		$ 0.15								$ 0.15			0.15		$ 0.15								$ 0.15			$ 0.15	$ 0.15	$ 0.15		$ 0.15
Common stock, par value (in dollars per share)																$ 0.001	$ 0.001																$ 0.001
Convertible Notes Payable																$ 2,093,640	$ 6,016,399
Debt Instrument, Maturity Date Range, Start																Dec. 31, 2010
Debt Instrument, Maturity Date Range, End																Apr. 30, 2011
Common stock, shares authorized																1,000,000,000	1,000,000,000										45,000,000
Long-term Debt, Gross											$ 250,000					$ 400,075	$ 50,000				$ 132,500	$ 25,000	$ 100,000	$ 132,500	$ 103,500			$ 66,667	$ 953,333		$ 50,000	$ 59,000						$ 40,000
Stock Issued (in shares)										4,076,923		4,000,000			40,000				59,228,334
Stock issued															$ 235,000	$ 0	$ 1,676,554	$ 6,828,293	$ 9,380,902
Stock Price:																$ 0.045	$ 0.141
Other Hanover Related Transactions [Member]
Issuance of notes							$ 340,522
Debt Instrument, Interest Rate, Stated Percentage							6.00%
Common Stock, Conversion Features							Prior to the date of this filing, all Magna Exchange Notes (including the $400K Magna note in Footnote 6) have been converted in full into 25,315,171 shares of our common stock in accordance with its terms and no longer remains outstanding
Sale Of Stock Under Equity Enhancement Program [Member]
Debt Instrument Purchase Price							$ 10,000,000
Stock Issued (in shares)							11,390,514
Sale Of Stock Under Equity Enhancement Program [Member] \| Hanover Purchase Agreement [Member]
Stock Issued During Period, Shares, Issued for Cash	8,000,000					4,400,000	6,990,514
Stock Price:	$ 0.0644					$ 0.0374	$ 0.0266
Ironridge Settlement [Member]
Common stock, par value (in dollars per share)																				$ 0.001
Subsequent Event, Description									The Order, together with the Stipulation for Settlement of Claims, which we refer to as the Stipulation, dated December 19, 2012, between us and Ironridge Global IV, Ltd., which we refer to as Ironridge, provides for the full and final settlement of Ironridge's $692,761 claim against us in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which we refer to as the Claim.
Common stock, shares authorized																				45,000,000
Stock Issued (in shares)									33,389,663
Stock issued									$ 692,761.29
Return Of Common Stock Shares																				11,610,337
Asher Note [Member]
Issuance of notes				$ 153,500												$ 103,500
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Instrument, Maturity Date				Aug. 14, 2013
Debt Instrument Purchase Price				$ 150,000
Debt Instrument Convertible Conversion Price In Percentage				65.00%
Outstanding Shares In Percentage				4.99%
Long-term Debt, Gross																									$ 103,500
Private Placements Of Convertible Notes To Hanover [Member]
Issuance of notes			$ 100,000
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument Purchase Price			$ 100,000
Outstanding Shares In Percentage			4.99%
Debt Instrument, Convertible, Conversion Price			$ 0.03
Debt Instrument, Maturity Date Range, Start			May 19, 2012
Debt Instrument, Maturity Date Range, End			Jun. 19, 2013
Long-term Debt, Gross																					$ 132,500			$ 132,500
Jmj Note [Member]
Issuance of notes								$ 125,000
Debt Instrument Purchase Price								$ 100,000
Closing Price Of Common Stock In Percentage								70.00%
Long-term Debt, Gross								$ 115,000
Tonaquint Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Convertible, Conversion Price		$ 0.16
Subsequent Event, Description		On December 13, 2012, we entered into an agreement, which we refer to as the Tonaquint Purchase Agreement, with Tonaquint, Inc., which we refer to as Tonaquint, whereby we issued Tonaquint a secured convertible promissory note for the initial principal sum of $890,000, which we refer to as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can be converted at a fixed price of $0.16 per share but is subject to reduction in the event that we issue shares below the conversion price of $0.16.
Convertible Notes Payable		$ 890,000
Debt Conversion, Description		On the closing date, Tonaquint (i) funded us with $490,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 2. Mortgage Note 1 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 8 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.

Label	Element	Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms	adxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	6 years
Adjustments To Additional Paid In Capital, Share Based Compensation, Stock Options, Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	$ 10,493
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 0.16
Stock Issued During Period, Shares, Conversion Of Convertible Securities	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	4,725,927
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	$ 306,500
Stock Issued During Period Value Share Based Compensation	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	10,493
Stock Issued During Period, Value, Conversion Of Convertible Securities	us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	660,000
Preferred Stock [Member]
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	$ (235,000)
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,418
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 235,000
Retroactive Restatement To Reflect Shares, Re Capitalization	adxs_RetroactiveRestatementToReflectSharesReCapitalization	(3,481)
Additional Paid-In Capital [Member]
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	$ 219,442
Adjustments To Additional Paid In Capital, Share Based Compensation, Stock Options, Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	10,493
Stock Issued During Period Value Share Based Compensation	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	10,493
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	40
Retained Earnings [Member]
Net Loss As Reported	us-gaap_NetIncomeLoss	(166,936)
Common Stock [Member]
Retroactive Restatement To Reflect Value Re Capitalization	adxs_RetroactiveRestatementToReflectValueReCapitalization	15,558
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 40
Retroactive Restatement To Reflect Shares, Re Capitalization	adxs_RetroactiveRestatementToReflectSharesReCapitalization	15,557,723